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I. Abstract
In order to spread infections, bacterial collagenases methodically unravel collagen
fibril in tissues. Collagen is the most abundant protein in the body, and can be found in
the skin, bone and cartilage [1]. Two collagenases, ColG and ColH, synergistically
dismantle collagen fibrils by seeking different weak links in the collagen structure. The
collagen-binding domain (CBD) of these collagenases binds to most vulnerable regions
in collagen [8]. Without CBDs, collagen fibril cannot be degraded.
Cells express collagen receptors in order to anchor themselves, which is a critical
step in cell proliferation. Binding sites for some collagen receptors, such as integrin and
interleukin-2, have been determined [4]. The goal of my project is to determine where
tandem CBD from ColG binds on rattus type I collagen. Out of the more than 20 different
types of collagen in the human body, this type of collagen is the most abundant [4].
Biophysical studies using collagen-like peptides have demonstrated that the CBD targets
less tightly wound (undertwisted) regions in the triple-helix [8]. Therefore, it is expected
that the CBD also targets proline poor regions in collagen. It is also expected that the
CBD does not interfere with binding of important anchoring proteins based on previous
studies of ColH.
In order to determine whether these hypotheses are correct, my approach is to use
a photo-reactive crosslinker to freeze the CBD-collagen complex [16]. The crosslinker
has a sulfhydryl reactive functional group. Adjacent to the collagen-binding cleft in CBD,
a cysteine mutation was introduced by means of an overlap extension polymerase chain
reaction (PCR). This cysteine mutation allows for the crosslinker to be attached by
forming a disulfide bridge. After performing the PCR reactions, the mutant proteins were
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successfully overexpressed and purified. Following purification, several crosslinkers
were attached to the cysteine residue, and the results were confirmed using mass
spectrometry. These attached photoreactive crosslinkers consists of a photo-reactive
functional group. After UV light exposure the cross-linker should be activated to attach to
the collagen forming a CBD-collagen complex. Future experiments then subjected the
complex to digestion by trypsin, and the tryptic fragments were analyzed by LC-MS/MS
(ESI mass spectrometry) to identify the location of CBD binding.
Fusion proteins of ColH CBD and signal molecules, such as cytokines, hormones
and growth factors, anchor themselves to rapidly remodeling collagen [15]. This
anchoring promotes tissue engineering and wound repairs in vivo [12, 13]. It also reduces
the amount of signal molecules required to achieve the desirable outcome while at the
same time reducing side effects. Although the tandem CBD from ColG is safe in vitro,
fusion proteins of the tandem CBD and signal molecules have not yet been made and
tested in vivo. My findings may contribute to the continuum of research to lead to
efficacious treatment options for wound repair and tissue engineering applications.
II. Introduction
Collagen is the most abundant protein in the body, and is distinct from other
proteins in that it comprises a triple helical structure made from three polypeptide chains
[1]. In order for the chains to form a triple helical structure, the amino acid Glycine (Gly)
has to be at every third position of the amino acid sequence [2]. This requirement causes
a repetitive Gly-X-Y sequence to be seen throughout most collagen amino acid
sequences, where X and Y are frequently seen to be the imino acids, proline and
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hydroxyproline [1]. The sporadic placement of this sequence leads to variability in the
structure and stability. [3]

Figure 1. Diagram of triple-helical collagen molecules in a fibril that was determined by using positive and
negative stains to produce a pattern [1].

There are more than 20 different types of collagen, but collagen types I, II, III,
V and XI are the most abundant in the body [1]. Type I collagen is found throughout the
body, except for in structures made out of cartilage [1]. This type of collagen typically
interacts with cell surfaces, extracellular matrix molecules, growth factors and
differentiation factors [4]. As the most abundant type of collagen in the body these
interactions lead to maintaining the integrity of most tissue samples [4]. Type II collagen
can be located in the cartilage, vitreous humour, and also during development in the
cornea [1]. Type III collagen is a major component of the extracellular matrix of the skin,
and is also found in the walls of arteries and many hollow internal organs, including the
intestine, liver and spleen. [1, 5, 6] It usually occurs in the same fibril with type I
collagen. Liu et al. showed that type III collagen plays a critical role in the development
of fibrils during the development of organs, because in the absence of type III collagen
organs failed to develop properly leading to functional failure [5]. The final two types of
collagen are minor components of tissue. In tissues, type V collagen and type XI
collagen, mostly form heterotypic fibrils with type I and type II collagen, respectively [1].
Collagen remodeling occurs during development, maintenance and regeneration
of tissues [7]. Any structural or metabolic abnormalities in this process can result in
various pathologic conditions and genetic diseases. Specifically, excess collagen
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remodeling activity can cause tumors and arthritis [7]. Collagen fibrils can act as a major
biomechanical scaffold allowing for cell attachment and anchorage of macromolecules
[1].
Bacterial collagenases bind to collagen, and it is hypothesized that they also target
remodeling collagen. These enzymes methodically unravel collagen fibril in tissues, to
spread infections, and cause gas gangrene. Two collagenases from Clostridium
histolyticum, ColG and ColH, synergistically dismantle collagen fibril by possibly
seeking different weak links in collagen [8]. As can be seen by looking at Figure 2, both
enzymes have segmental structures but the key difference between these two enzymes is
that ColG has two CBDs.
Figure 2. Collagenase ColG and
ColH schematic diagram [9] .

The segmental structure for ColG includes the following domains, i.e. S1, S2, S3a
and S3b [9]. Every segment is expected to possess a different role. The S1 is the catalytic
domain that hydrolyzes the collagen. Various functions have been suggested for the S2
domain. It is proposed to be a spacer. It is also proposed to be an assistant for collagen
binding and to cause collagen fibril swelling. The S3a and S3b domain anchor the
enzyme to collagen [10, 11].
The collagen-binding domain of ColH (S3) has systemic effects, by anchoring
fused drugs at the site of injection with prolonged half-life. A fusion protein of collagen
binding domain and parathyroid hormone (PTH-s3) is being developed as a treatment
option for osteoporosis. Ponnapakkam et al. observed that either monthly or weekly
administration of PTH-CBD increased bone mineral density (BMD) in mice without
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causing hypercalcemia, which is a common side effect in present PTH therapy [12, 13].
Other forms of this drug were used to help prevent chemotherapy-induced hair loss, bone
fracture repair, and bone transplantation [14].
ColH domains S2b-S3 bind more tightly to collagen. Dr. Uchida, Dr. Matsushita
and others demonstrated that when the collagen-binding segment of ColH (s2b-s3) is
used as a drug carrier, it anchors the fused basic fibroblast growth factor (bFGF) at the
site of injection with prolonged half-life [15]. The results also showed that bFGF-s2b-s3
promoted bone healing much faster than bFGF-s3 and bFGF alone [15]. Tandem CBD
from ColG (S3a-S3b) is known to bind the tightest to collagen, and therefore it may be a
better drug delivery vehicle than ColH (s2b-s3).
Collagen-binding cleft of CBD has been identified by X-Ray Crystallography,
and it has been demonstrated by Sakon’s lab that it targets loosely wound collagen-like
peptide [8]. However, binding site on bona fide collagen has not been elucidated. To
better control drug and extracellular matrix interaction, collagen-CBD interaction needs
to be elucidated. It is expected that tandem CBD will target one of the six regions in type
I collagen that are predicted to be rich in underwound triple helices. It is also expected
that because remodeling collagen fibril may make undertwisted regions more accessible
to CBD, it will bind to these regions, and can be valuable for diagnostic and therapeutic
treatments for cancer.
III.

Overview of Experimental Approach
Photoreactive crosslinking reagents are used to capture and freeze these

momentary collagen-CBD contacts to study the collagen-CBD interactions [16]. The
rapid reactivity on crosslinkers allows interactions to be seized in a complex stable
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enough for isolation and characterization. To attach such reagent to ColGS3aS3b,
cysteine mutations were introduced adjacent to collagen-binding clefts in the following
mutants using overlap extension polymerase chain reactions (PCR): ColGS3a(S879C),
ColGS3aS3b(Y996A, S997C), ColGS3aS3b(S997C), ColGS3aS3b(S879C),
ColGS3b(Y996A, S997C).
Overlap extension using PCR can be used to introduce site-directed mutations
into a wild type DNA sequence. This procedure involves two PCR reactions. Looking at
Figure 3, the first PCR reaction involves the generation of two mutant DNA strands with
overlapping ends. In order to perform this reaction, two complementary primers (Forward
and Reverse) must be designed to have the desired nucleotide mutation. A wild type
DNA plasmid is used as a base template. After denaturation by heat, separate vials allow
the Forward and Reverse primers to anneal individually to the base template along with a
complementary primer. In the case of this experiment, a 5’ pGEX primer was used with
the Reverse primer, and the 3’ pGEX was used with the Forward primer. A DNA
polymerase is used to elongate the primers until two new mutant DNA strands are
formed.

Figure 3. Production of mutant DNA
fragments using PCR.

After generating the two mutant DNA strands, a second PCR is performed in
order to allow for the recombination and amplification of these strands. Looking at Figure
4, the first step of this reaction is to denature the DNA allowing for the 3’ complementary
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ends to anneal together. This places the mutation of interest in the overlapping regions.
After the two strands anneal together, DNA polymerase elongates the strands. 3’pGEX
and 5’pGEX primers anneal to the strands allowing for replication of the two mutant
DNA strands. This results in two complementary DNA strands. As can be seen in Figure
5, the resulting complementary DNA strands can be inserted into an expression vector
after cleavage using XhoI and EcoRI-HF. By placing, the mutant CBD in the expression
vector it forms a plasmid, which can then be inserted into Escherichia Coli (E. Coli)
bacterial cells for DNA production.

Figure 4. Overlapping fragments allow for
elongation of mutant DNA strands.

Figure 5. Cleavage by enzymes to place mutant CBD in
the expression vector.

In order to confirm that the PCR produced desired results, the DNA strands can
be sequenced using The Big Dye Terminator v1.1 Cycle Sequencing Kit and a
sequencing machine. This method of analysis uses a DNA polymerase to reproduce the
mutant DNA sequences using deoxynucleosidetriphosphates (dNTPs), which are
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fluorescently labeled nucleotides. Di-deoxynucleotidetriphosphates (ddNTPs) are used to
terminate DNA strand elongation. After running the prepared DNA strands in the
sequencing machine, a sequencing chromatogram is produced. As shown in Figure 6, the
DNA chromatogram shows different colored peaks that represent the four different
nucleotides. This is because all four dNTPs have a different colored fluorescent tag.
After analyzing the graph to determining the sequences, the experimental DNA strand
sequences and expected DNA sequences can be compared.

Figure 6. Example of a DNA chromatogram obtained
after sequencing.

After confirming the sequence of the mutations, the plasmids were introduced into
E. coli bacteria in order to produce the proteins. These proteins were purified using GSTtag and glutathione sepharose beads. Glutathione sepharose beads have a high affinity for
GST, and allow for the binding of GST tagged proteins to the column. After cleaving the
GST tag off the proteins, the GST tag will remain bound to the column, and the eluent
will contain purified protein with little to no traces of impurities.
If a large amount of impurities were left in the eluent, the protein was further
purified using a strong anionic purification column using Q-sepharose beads. Qsepharose beads are positively charged and allow for binding of negatively charged
molecules. A buffer without salt is added to collect any protein that does not bind to the
Q-sepharose beads. Afterwards, a sodium chloride (NaCl) concentration gradient is used
to slowly elute the protein from the column.
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Each mutant protein was produced for a different purpose. First, in order to
determine where the S3a segment interacts with collagen, ColGS3a(S879C) and
ColGS3aS3b(S879C) were produced. Also, in order to determine where the S3b segment
binds on collagen ColGS3aS3b(S997C) was created. Finally, in order to rule-out any
nonspecific binding sites, ColGS3aS3b(Y996A, S997C) and ColGS3b(Y996A, S997C)
were produced. These last two mutants should not bind to collagen.
The mutation of focus has been ColGS3aS3b(S997C). A binding assay was
performed, and it was determined that ColGS3aS3b(S997C) binds to collagen, as well as
the wild type. As mentioned before, this protein consists of two collagen binding
domains. These domains exist tandem to each other probably as a result of gene
duplication, and as a result binds tightest to collagen fibrils [12]. It is expected that both
domains bind to two tropocollagen molecules, and therefore has the potential of being a
longer lasting drug delivery carrier.
In order to assess the potential for the tandem CBDs to be a long lasting and
localized drug delivery carrier photoreactive crosslinkers were successfully attached to
the cysteine mutation. The four crosslinkers used include fluorescein-5-malemide, MTSBP-Bio Biotin, N-[4-(p-azidosalicylamido) butyl]-3'(2'-pyridyldithio)propionamide
(APDP), and azide N-((2-pyridyldithio)ethyl)-4-azidosalicylamide (PEAS).
There are three key elements of the APDP and PEAS crosslinkers that can be seen
in Figure 7. First there is a cysteine reactive portion that will react with the introduced
cysteine mutation in the protein. Second there is a photoreactive element that can be
excited by UV light (usually at <360nm) and will bind to collagen. Finally, there is a
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disulfide bridge present in both of these crosslinkers that can be reduced and has the
potential of being helpful in future experiments.

Figure 7. APDP and PEAS crosslinkers; diagram created by Keisuke
Tanaka.

The MTS-BP-Bio biotin crosslinker was initially used because it was expected to
help purify the CBD complex. There are four major components of this crosslinker that
are shown in Figure 8. Like APDP and PEAS, there is a cysteine reactive portion that
can bind to the cysteine mutant, and a photoreactive portion that becomes reactive upon
UV exposure. Also, present is the disulfide bridge. Unique to this cross-linker is the
biotin substituent that can bind to streptavidin beads in a purification column.

Figure 8. MTS-BP-Bio crosslinker figure.

Fluorescien-5-malemide was initially used
to study the distribution of tandem CBD. However,
previous in vivo work published by Dr. Sakon demonstrated that CBD targeted skin, bone
and intestine [13, 14]. It was hypothesized that CBD may preferentially target rapidly
remodeling collagen. In order to determine where CBD binds in vitro, CBD was labeled
with fluorescein-5-maleimide (seen in Figure 9). Fluorescein appears fluorescent under
UV light, and therefore can be clearly seen under microscope. The compound allowed
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fluorescent labeling of sulfhydryl group on CBD. Fluorescein labeled CBD was purified
from unreacted fluorescein-5-maleimide by using size exclusion chromatography
column. It was then introduced into pancreatic cancer cells to observe binding.

Figure 9. Fluorescein-5-maleimide crosslinker.

In order to attach cysteine reactive crosslinkers to the CBD, the disulfide bridges
in the CBD must be reduced using dithiothreitol (DTT), a common redox reagent. After
reduction and dialysis the protein was analyzed by 12% SDS-PAGE. If it was determined
that the crosslinker was successfully attached, then the crosslinker attached CBD
undergoes cross-linking to solubilized tropocollagen from rattus source. As can be seen
in Figure 10, the cross-linker will bind to collagen after UV exposure. Once exposed to
UV light, the collagen and collagen complex are separated from each other by running
SDS gel. Faint bands above β and α bands of collagen correspond to the crosslinked
complex. The crosslinking assay can then be analyzed by 2-D electrophoresis using 5%
SDS-PAGE to determine the location of linkage.

Figure 10. Diagram of cross-linking assay.
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After SDS-PAGE confirmation, the crosslinking assay results are produced in
large quantity in order to obtain enough sample to analyze by liquid chromatography
electrospray ionization (ESI) tandem mass spectrometry (LC-MS/MS). SDS-PAGE gel
spots corresponding to the crosslinked complex were reduced/alkylated using DTT/
iodoacetamide before the in gel trypsin digestion. Looking at Figure 11, reduction by
DTT releases tandem CBD from the crosslinker. Part of the crosslinker is left behind as
the signature to be identified by LC-MS/MS. Alkylation modifies the thiol group by
attaching iodoacetamide to form carbamidomethylated crosslinker. Trypsin hydrolyzes
the peptide at the C-terminal side of arginine (R) and lysine (K), forming small peptide
fragments. These small peptides make identifying the binding site from collagen much
easier by LC-MS/MS. The individual tryptic peptides undergo MS/MS fragmentation in
order to derive the amino acid sequence information corresponding to individual tryptic
peptides from the collagen.
Figure 11. Work flow
used in LC-MS/MS analysis to
determine the CBD binding site
in collagen.

Collagen has several possible post translational modifications such as P and K
(oxidation), N and Q (deamidation), K (galactosylation), and K (glucosylgalactosyl). This
makes it difficult to map the sequence of collagen because there can be many different
post translational modification combinations located in one tryptic peptide. Therefore, it
is necessary to not only perform LC but also perform on the fly MS/MS to map the
sequence and modifications exits in any given tryptic peptide. LC was performed by
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using reverse phase nano column. Reversed phase chromatography involves using a
hydrophobic stationary phase, that includes regular phase silica particles modified by –
(CH2)17CH3 chain or C18 bonded silica. This non polar stationary phase allows for
hydrophobic molecules in the mobile phase to be retained longer, while allowing
hydrophilic molecules in the mobile phase to elute first. After being separated by the
reverse phase liquid chromatograph, ESI-MS/MS will identify the collagen tryptic
peptides with the crosslinker attached by looking at the mass differences. For instance,
the APDP crosslinker with the carbamidomethyl group changes the tryptic peptide mass
by 366Da. This modification can be searched in the data base to identify the tryptic
peptide with APDP.
MASCOT software from matrix science (http://www.matrixscience.com) and
skyline software from (http://skyline.gs.washington.edu) are used to filter MS/MS data.
MASCOT or skyline software uses mathematical algorithms and some statistical software
to identify peptides with at least 95% confidence. For the peptide to be considered a
reliable identification, both MASCOT and skyline had to identify the peptide as a good
identification. False positive identifications are filtered out by searching MS/MS data for
the α1 and α2 chains in the same way as the MS/MS data from the crosslinked complex.
IV. Methods
A. Mutagenesis Projects by Overlap Extension PCR
In order to introduce the desired mutations into the amino acid sequence of the
wild type DNA, primers were designed that could be amplified using polymerase chain
reactions (PCR). In order to design these primers, the DNA sequence for the specific
mutagenesis was determined and analyzed in order to determine which codon for the
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desired amino acid mutation should be introduced. Ideally, the best way to introduce a
mutation is by only changing one of the nucleotides because this increases the likelihood
that the wild type DNA will be successfully mutated.
For ColG3aS3b(S997C), the reverse (R) and forward (F) primers designed were
as follows, :
R: AACTCATAGTTTCCTGATCCGCAGTATTTATAAACAAGTAGAT
F: ATCTACTTGTTTATAAATACTGCGGATCAGGAAACTATGAGTT
The original DNA sequence that was altered using PCR was the vector pCHG112,
which represents the sequence for the wild type ColGS3aS3b.
For ColG3aS3b(Y996A/S997C) and ColGS3b(Y996A/S997C), one primer was
designed because the mutations of interest is located in the S3b CBD for both mutations.
The primers designed consisted of the following sequences:
R:
TAATAGATGAACAAATATTTCGGAGTCCTAGTCCTTTGATACTCAA
F: ATTATCTACTTGTTTATAAAGCCTCAGGATCAGGAAACTATGA
Additionally, these primers only contain an alanine mutation because the original
DNA sequence that was used in the PCR reaction was ColG3aS3b(S997C) and
ColGS3b(S997C) respectively. These primers only changed two of three nucleotides in
the original sequence from tyrosine (TAC) to alanine (GCC).
For ColG3aS3b(Y994A/S997C), the designed primers were as following:
R:AGCAACAAGTAGATAATATTTTC
F:GAAAATATTATCTACTTGTTGCTAAATACTGCGGATCAGGAAA
The original DNA sequence that was altered was ColGS3aS3b(S997C).
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All of these primers were ordered through the company Fasmac Bio (Okada,
Atsugi Kanagawa). After receiving the primers, the tubes containing the primers were
centrifuged and autoclaved distilled water (MilliQ) was added to solubilize the primers.
Working primers were made by taking ten microliters of each primer and diluting it with
MilliQ water for a total amount of 100μL working primer.
The reaction mixtures for the first round of PCR were prepared by placing 10μL
5x PrimeSTAR Buffer, 4μL dNTP Mixture, 1μL F Primer (R Primer), 1μL pGEX primer
(5’ pGEX primer), 1μL DNA Plasmid, and 0.5μL DNA polymerase (PrimeSTAR
Enzyme) into two small PCR vials. The reaction vials were then placed in a thermo
cycler at 98°C for 10 seconds, 55°C for 5 seconds, and 72°C for 1min/kilobase for a total
of 30 cycles.These reaction mixtures formed two mutant DNA strands that were used in a
second PCR reaction.
For each mutagenesis project, a different starting DNA plasmid was used. For
ColGS3aS3b(Y996A/S997C) and ColGS3aS3b(Y994A/S997C), DNA plasmid E022 was
used as the base template. This plasmid was created by Ryan Bauer and consists of the
DNA sequence for ColGS3aS3b(S997C). Additionally, for ColGS3b(Y996A/S997C), the
DNA plasmid E006 served as the base template. This plasmid was also created by Ryan
Bauer and contains DNA plasmid for ColGS3b(S997C). Before using these plasmids, the
sequences were confirmed by sequencing the DNA.
Agarose gel electrophoresis was used to analyze and confirm that the amplified
DNA plasmids contained the proper amount of base pairs. In order to perform the agarose
gel electrophoresis, 1.5% agarose gel was created by measuring out 1.5 g of agarose. 100
mL of Tris/Borate/EDTA (TBE) buffer was added to the Erlenmeyer flask, and the
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solution was microwaved for five minutes. Before solidification the mixture was poured
into the agarose gel-casting stand. After solidification the gels were removed and placed
in a container of TBE solution.
In order to conserve resources, the gel was cut in order to contain the required
amount of wells for analysis. The gel was then placed in the horizontal electrophoresis
unit. A small amount of amplified primer was mixed with 1:5 volume of primer to blue
dye. The two amplified primers were placed into two separate wells, and a DNA
molecular weight marker was added to a third well. The electrophoresis unit was allowed
to run for approximately 30 minutes. The unit was turned off before the sample could run
off the agar gel. The gel was placed into ethidium bromide. From this point on gloves
were used to handle the gel because ethidium bromide is a carcinogen. After soaking in
the ethidium bromide solution for 15 minutes, the gel was washed off with water and
placed into a UV machine that contained a camera. A picture was taken of the gel
exposed to UV light, in order to analyze the bands for the correct number of DNA base
pairs.
After confirmation that the primers contained the proper amount of base pairs, the
DNA plasmids were purified using the QIAqucik PCR Purification Kit. In order to use
this kit, two 1.5 mL vials were labeled with reverse and forward so that the solutions
could be recognized. The entire PCR mixture from the first PCR was placed into the
appropriately labeled 1.5 mL vial. The instructions from the kit were followed until step
7, in which water was used instead of Buffer EB. At the end of the purification, the flow
through was collected and a NanoDrop UV-Vis spectrophotometer was used to determine
the concentration of DNA in the sample.
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In order to join the overlapping ends of the forward and reverse primers, a second
PCR reaction was performed. In order to perform this reaction a small PCR vial was
prepared containing 10μL 5x PrimeSTAR Buffer, 4μL dNTP Mixture, 1μL 5’ pGEX
primer, 1μL 3’ pGEX primer, forward primer (total concentration of 50ng/ 50μL), reverse
Primer (total concentration of 50ng/50µL), 1μL DNA Plasmid, and 0.5 P DNA
polymerase (PrimeSTAR Enzyme). After mixing these solutions the total volume was
adjusted to 50μL using MilliQ water. The reaction vials were then placed in a thermo
cycler at 98°C for 10 seconds, 55°C for 5 seconds, and 72°C for 1min/kilobase for a total
of 30 cycles.
The vials were then left in the thermocycler at 4°C overnight. The next day the
sample was analyzed by agarose gel electrophoresis using the already mentioned
protocol. If the sequence was correct the QIAquick PCR Purification was used to purify
the sample. Afterwards, an addition reaction was performed by mixing small PCR vials
containing 8μL PCR Product, 1μL 10x Buffer, 0.5μL dATP, and 0.5nd A-Overhang
Enzyme. The reaction mixture was then incubated at 65°C for ten minutes. Then 1 μL of
the addition reaction mixture was added directly to a Ligation Mixture, which contained
1μL pMD20-T Vector, 3μL MilliQ water, and 5μL Ligation Mighty Mix. This mixture
was mixed by flicking the vial with a fingertip, centrifuged and then placed in an
incubator at 16°C for thirty minutes.
Afterwards the plasmids were introduced into DH5α E.Coli cells. The DH5α cells
were used to obtain DNA that could be sequenced to confirm that the mutation was
introduced into the plasmid DNA. E. coli cells are extremely sensitive to heat and should
be kept on ice at all times. In order to prevent contamination, the 10μL solution of
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ligated mixture was introduced into the vial of DH5α E. coli cells underneath a gas hood.
The vial was incubated on ice for thirty minutes, transferred to an incubator at 42°C for
ninety seconds and then placed on ice for two minutes. Once again in the hood, 900 μL of
SOC media was added to the cells. The mixture was then incubated at 37°C for 1 hour.
In order to create, the SOC media 10g Bacto Tryptone, 2.5g Bacto Yeast Extract,
0.25g Sodium Chloride and 0.093g Potassium Chloride were dissolved in 400 mL of
deionized water. The pH was adjusted to 7.0 using Sodium Hydroxide. After adjusting
the pH the total volume of the solution was brought up to 500mL. This solution was then
divided into five 100mL aliquots. Before using the SOC media, 1.8mL of 20% glucose (a
final concentration of 20mM) and 1mL of 1M Magnesium Chloride (a final concentration
of 10mM) must be added to the 100mL aliquot.
In order to screen bacteria production, these cells were applied to two LB agarose
gel with ampicillin (AMP) plates. In the hood, the plates were labeled with the mutation,
date, and either Plate #1 or Plate #2. On Plate #1, 50μL of the cells were placed in the
middle of the plate on a spin table. While spinning the plate, an “L” shaped instrument
was used to spread the bacteria out evenly over the plate. In order to ensure proper colony
formation, this must be done gently without breaking the gel. For Plate #2, the remaining
solution was centrifuged for one minute at maximum speed. Then approximately 850μL
was removed from the top of the E. coli cells. After mixing the cells with the remaining
100μL of solution, the cells were plated onto Plate # 2 following the same procedure as
Plate #1. The plates were left overnight in the incubator at 37°C.
In order to prepare the LB agarose gel plates, 100mL of deionized water, 2.5g of
LB Medium, and 1.5g of Agar were added to an Erlenmeyer flask. The flask was covered
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with aluminum foil and then autoclaved for 15 minutes at 121°C. It was allowed to cool
to a temperature that could be handled by hand. Before the mixture solidified 100μL
AMP (50 mg/mL) was added to the broth. In the gas hood, the broth was then poured into
the plates until the plates were 20% full. The LB agarose was allowed to solidify and then
the plates were sealed in a plastic bag to prevent dehydration of the gel.
After allowing the colonies to grow to a sufficient size, two 10mL vials were
prepared by labeling #1 and #2. In the hood, 5mL of LB broth was added to both of the
vials. Then, 5μL of AMP was added to the broth. After sterilizing an inoculating loop by
fire, the loop was used to transfer one colony into vial #1. The loop was sterilized again
and a different colony was transferred to vial #2. The vials were placed in a shaker at
37°C to be left overnight. Two different colonies were incubated in order to increase the
likelihood of having a correct sequence.
After allowing the culture to grow overnight, the bacterial broth was purified in
order to obtain DNA plasmid that could be sequenced. In order to do this 1mL of both
cultures were placed in two 1.5 mL vials labeled #1, for Culture #1, and vial labeled #2,
for Culture #2. These vials were centrifuged for one minute at high speed. The
supernatant was dumped off the top of the bacterial cells, and then another 1 mL portion
was added to each vial. The vials were once again centrifuged for one minute at high
speed. The SV Mini Preps Isolation kit was used to isolate the plasmid DNA from the
protein. The concentration of DNA in the sample was recorded using the NanoDrop UVVis spectrophotometer.
After collecting the plasmids a 1.5% agarose gel analysis was performed in order
to confirm the number of nucleotides in the DNA sequence. In order to analyze by agar
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gel the DNA needed to be cut using the two enzymes EcoRI-HF and XHOI. The
following reagents were mixed in a vial containing, ~200ng/20μL Plasmid DNA, 2μL10x
buffer (CutSmart B), 1μL Enzyme 1(EcoRI-HF), and 1μL Enzyme 2 (XHOI). One vial
was made for each culture. After adding MilliQ water to make the total volume 20μL the
solutions were mixed and incubated at 37°C for one hour. The electrophoresis was ran in
the same way as mentioned above. After confirmation of the correct number of base pairs
present in the DNA sequence, the plasmids were prepared for DNA sequencing. Also,
1200μL of the E. coli culture was mixed with 600μL 50% Glycerol. These cultures were
then placed in the freezer after labeling with appropriate names.
If the number of nucleotides appeared to be incorrect on the gel, then a procedure
known as colony PCR was performed in order to find a colony with the correct number of
nucleotides. This procedure was used for mutations ColGS3b(Y996A/S997C) and
ColGS3aS3b(Y996A/S997C). In order to do this eight 1.5mL Vials were labeled 1-7 and
C. After labeling, 20μL of MilliQ water was added to each vial. A master plate was
labeled in order to keep track of the colonies that were placed in each vial. After taking
up one colony using a sterilized inoculating loop, the master plate was streaked and then
the colony was mixed in the appropriate vial. This was done for vials labeled 1-7.
Afterwards, a master buffer was mixed using 18μL10X PCR Buffer, 14.4μL 4X DNTP,
9μL 5’ pGEX primer (20μM), 9μL 3’pGEX primer (20μM), 119.7μL deionized Water,
and 0.9μL rTAQ Polymerase.
This master buffer was divided into 20μL aliquots by placing it in 8 small PCR
vials. Afterwards, 1μL of bacterial water from the vials labeled 1-7 and C were placed
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into each separate PCR vial. These PCR vials were placed in the thermocycler at 94°C for
5 min, 94°C for 30 seconds, 50°C for 30 seconds, 74°C for 1 minutes, and 4°C for ∞.
After this protocol was complete, a 1.5% agar gel was run in order to compare
colonies. If there was a colony which had the correct number of base pairs the colony
from the master plate was transferred to the LB broth and left in the incubator at 37°C
overnight to restart the process.
After confirming that the DNA plasmid has the correct number of base pairs, the
plasmid DNA was treated using The Big Dye Terminator v1.1 Cycle Sequencing Kit.
This kit prepares the plasmid for DNA sequencing. The 3’ and 5’ primers were
sequenced separately. ~200ng/20μL collected double stranded DNA plasmid was mixed
with 8μL Terminator Ready Reaction Mix in two separate vials. In one tube labeled 3’, 2
μL1.6pmol/μL 3’ PGEX primer was added. In a second vial labeled 5’, 2μL of
1.6pmol/μL 5’PGEX primer was added. MilliQ water was added to both vials to make
the total volume 20μL. The samples were then placed in the thermocycler at 96°C for 1
min. Then, the thermocycler repeated 96°C for 10 seconds, 50°C for 5 seconds, and 60°C
for 4 minutes 25 times. It then cooled to 4°C for ∞.
Once this protocol was done a termination sequence was used in order to get rid
of extra nucleotides at the end of the sequence. A solution of 20μL PCR Product, 90μL
SAM, and 20μL XT was mixed for each primer. The mixtures were placed in a vortex for
30 minutes and centrifuged at 1000G for 2 minutes. The clear solution from each vial
were transferred to individual wells in a plate used for sequencing. A buffer was created
using 27 mL of water with 3mL of 10x Running Buffer. This buffer was used for the
sequencing machine.
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After running the sequencing machine, the data was collected and a sequencing
chromatogram was analyzed. If the peaks were clear then the sequence could be analyzed
to determine if it is the correct sequence. If the experimental sequence was correct, then
the plasmids were digested by first preparing a vial with 16μL final PCR product, 2μL
Cutsmart Buffer, 1μL Eco-RI-HF, and 1μL XhoI. Then, another vial was prepared with
~500ng/20μL PGEX-4T-2, 2μL Cutsmart Buffer, 1μL Eco-RI-HF, and 1μL XhoI. These
vials were incubated for an hour at 37°C, and then an agar gel was run using 20μL of
DNA plasmid and 2.2μL10x loading buffer.
Two different wells are used for the electrophoresis for the 3’ and 5’ DNA
plasmid. After finishing the electrophoresis, the gel was placed in ethidium bromide for
15 minutes. The gel was then placed under UV light so that the bands could be clearly
seen. The bands were cut out of the gel using forceps and an X-Acto knife, while wearing
a facemask to protect the eyes from the UV light, and gloves to prevent exposure to
ethidium bromide. This procedure must be done quickly so that the UV light doesn’t
damage the DNA plasmids which could produce unwanted DNA mutations. The weight
of two 1.5mL vials was recorded and then the 5’ and 3’ plasmid gel pieces were placed
into the two separate 1.5mL vials. The weight of the vials with the gel piece was
measured. The weight before and after were subtracted in order to determine the weight
of the gel pieces. This information was then used to determine the amount of a solution
that was used in Qiagan QIAquick Gel Extraction Kit protocol. After extracting the DNA
from the gel following the protocol, a vial containing 10μL of insert DNA (pCHC302)
and 10μL of expression vector was prepared. 17μL of this solution was placed in a new
vial containing 2μL ligation buffer and 1μL T4 DNA Ligase for a total volume of 20μL.
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In order to start protein production the plasmids were introduced into BL21-RIL E. coli
cells following the same procedure that was performed for introducing the cells into DH5
α cells. The cells were then plated on LB agarose plate with Amp and CM.
The above described protocol was followed until certain problems were
encountered that needed to be resolved using different experiments. While creating
ColGS3b(Y996A,S997C) and ColGS3aS3b(Y996A,S997C) there was problems with
getting the correct plasmid after transforming the DNA plasmid in DH5α. After purifying
the DNA plasmids, the plasmids were cleaved using the enzymes Eco-RI and XhoI. After
running the agar gel it was determined that the plasmids were incorrect because the
plasmid was not cleaved into two parts. The first correction method tried was performing
the transformation process without the TA-cloning step. In order to do this we prepared a
vial containing 16μL final PCR product, 2μL Cutsmart Buffer, 1μL Eco-RI-HF, and 1μL
XhoI. Another vial was prepared containing ~500ng/20μL PGEX-4T-2, 2μL Cutsmart
Buffer, 1μL Eco-RI-HF, and 1μL XhoI. MilliQ water was added to this vial to make the
final volume 20μL. These two vials were incubated at 37°C for 1 hour.
The sample was run in an agar gel and placed in ethidium bromide. The bands
were extracted from the gel by using an X-Acto knife. In order to prevent the plasmid
from being burned this extraction procedure has to be done quickly. After extracting the
band, the QIAquick Gel Extraction Kit was used in order to obtain the plasmid. Then,
10μL of both vials was placed into one vial. 17μL of this sample was placed in another
vial with 2μL Ligation Buffer and 1μL T4 DNA Ligase. This vial was then incubated at
16°C for 1 hour. This plasmid was then transformed into DH5α competent cells and
plated on LB+ amp plates. The plates were left overnight at 37°C. If colonies were
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present then the broth was inoculated in order to collect the plasmids to be sequenced.
However, for the two attempts that were made at this method it didn’t work.
For ColGS3b(Y996A,S997C) after repeated failures, the experiment was
performed in large scale by concentrating the sample using ethanol precipitate. In order to
do this 1.5μL 3M sodium acetate (pH 7.0), 37.5μL Absolute Ethanol, and 15μL of two
different colonies plasmid were distributed in two different vials. The vials were placed
in the freezer at -80°C overnight. The mixture was thawed and then spun down at 15K
rpm for 15 minutes. The supernatant was removed and the plasmid was washed with
200μL 70% ethanol. The mixture was spun down at 15K rpm for 5 min. The plasmids
were air-dried by vacuum. Then 5μL TE was added to dried plasmids and the plasmid
was analyzed by SDS-PAGE. One of the plasmids appeared to have the correct cleavage,
therefore the plasmid underwent sequencing to determine if the correct sequence had
been introduced.
The sequence was incorrect and therefore two new colonies were chosen from
the colony PCR plate. After performing the PCR reactions and running agar gel
electrophoresis, the cleaved bands were not clear on the gel but the sequencing solution
had already been prepared so the plasmids were sequenced. After analyzing the results, it
was clear that the correct sequence had been introduced into the plasmid. The plasmids
underwent the rest of the procedure without any major problems and were transformed
into BL21-RIL cells to begin protein production.
For ColGS3aS3b(Y996A,S997C) the process was repeated with the TA cloning
step and a plasmid was obtained that could be sequenced. After correcting this part, the
steps were continued until another major problem was encountered. Before transforming

27

into DH5α cells, the agar gel electrophoresis did not show the desired results. Recall that
several experiments had been performed to get to this point. Therefore each step had to
be checked in order to determine which step was having issues. In order to do this, at
each step a small sample was taken out of the product to be analyzed by agar gel
electrophoresis. Also, all the vectors were analyzed by agar electrophoresis in order to
confirm that they were correct. After performing the experiment in large scale by ethanol
precipitate, it was determined that extraction step, where the plasmid is extracted from
the agar gel pieces, was the step having issues. There were no bands at all. After
repeating the extraction step with supervision to analyze the where error was introduce, it
was determined that the error was caused by not removing all of the cleaning solution for
the Extraction Kit. This error would prevent the DNA plasmid from leaving the gel, and
therefore explains the lack of bands in the agar gel. After correcting this step the rest of
the procedure was completed without problems and protein production began.
B.

Protein Production

In order to start protein production, 10μL of the double stranded plasmids were
transformed into BL21-RIL cells using the same procedure that was used for the DH5α
cells. These cells were then plated onto LB agarose plates with AMP and
chloramphenicol (CM) using the previously stated method. The plates were left overnight
at 37°C, BL21 cells grow at quicker rate then the DH5α cells so the transformation
process for BL21 cells was started later in the evening.
On the same day that the cells were plated, 2xYT-G medium was prepared by first
dissolving 16g/L tryptone, 10g/L yeast extract, and 5g/L sodium chloride in 800mL of
deionized water. The pH of this solution was adjusted to 7 using sodium hydroxide. The
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volume was adjusted to 900mL and then was autoclaved at 121°C for 20 minutes. After
the solution had cooled 100mL of 20% glucose was added to the medium and then agar
(1.2-1.5%).
The next day, if colonies were present on the plate, protein production began.
One 25 mL autoclaved Erlenmeyer flask with a pink cap was filled with 10mL of 2xYTG, and then 10μL of CM and AMP were added. One colony was added to the flask and
the culture was incubated in a shaker for 12 hours at 37°C. During this time, four 1L
Erlenmeyer flasks were autoclaved at 121°C for 20 minutes. These flasks were necessary
for the large scale production that occurs the next day. After the 12-hour incubation, one
300mL autoclaved Erlenmeyer flask was filled with 120mL of 2xYT-G+AMP+CM. 6mL
of the incubated culture was added to the 300mL flask. The flask was left in the
incubated shaker at 37°C for at least twelve hours.
The next day four 1L autoclaved Erlenmeyer flasks were filled with 500mL of
2xYT-G+AMP+CM. 25mL of the culture that was left overnight was added to each flask.
These flasks were placed in the incubated shaker at 37°C. After an hour, the optical
density was checked. Once the optical density reached 0.7, 5mL of IBTG was added to
each flask in order to induce protein production. IBTG is stored in the freezer and
therefore must be taken out of the freezer 30 minutes before needed in order to thaw.
After adding the IBTG, the flasks were left in the shaking incubator for two hours.
During this two hour time period, 20mL of PMSF was made by mixing 20mL of 1isopropanol with 0.348g PMSF. Also, during this time the large centrifuge was turned on
to allow time for cooling. Before using the PMSF solution, all the hairpin needles must
be completely dissolved in the solution.
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At the end of the two hours, 5mL of PMSF was added to each flask. Then four
large centrifuge tubes were obtained. The contents of one Erlenmeyer flask could fit into
two of the large centrifuge tubes. After filling four of tubes, they were balanced and then
placed into the large centrifuge. The tubes were spun for 10 minutes at 60000rpm. After
spinning the tubes, the supernatant from each tube was poured back into the large
Erlenmeyer flask. The same centrifuge tubes were filled with the cultures from the other
two flasks and the process was repeated. At this point the cells can be frozen in the
freezer at -80°C and left overnight. In order to dispose of the bacterial waste, the
Erlenmeyer flasks with the supernatant were autoclaved and then the waste dumped down
the drain.
The next step involves suspending the cells using PMSF with PBS. This solution
was made by first pouring 90mL of deionized water and 10mL of 10xPBS into a 200mL
beaker. Afterwards, 1.1mL of 1-isopropanol was mixed with 0.018g of PMSF. These two
solutions were mixed together. The cells were suspended using a pipette and the PMSF
with PBS solution. 5mL of this solution was added to the first tube. The cells were
suspended into the solution, which was then transferred to the next tube. The cells in the
next tube were suspended. This was done for all the tubes. Then this process was
repeated two more times in order to ensure that all the cells were present in the solution.
After suspending the cells, the French Pressure Cell Press was used to break open
the cells. After loading the cells in the French Press cell, the pressure was kept constant at
640psi. In order to ensure that all the cells were broken apart the pressure had to remain
constant. Then two smaller tubes were filled with the broken cells, and 1.16mL of 20%
Triton was used to wash the protein of any impurities. The tubes were mixed for 30
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minutes and during this time the large centrifuge was turned on in order to allow cooling.
After the 30 minutes, the tubes were placed in the centrifuge. The tubes were spun down
at 15000rpm for 30 minutes. The centrifugation was done to get rid of the cellular debris
and to separate the protein. After the thirty minute time period, the supernatant (protein)
was poured into two new tubes and they were placed in the centrifuge at 15000rpm for 30
minutes.
During this time, glutathione sepharose beads were washed using PBS. In order to
make the PBS, 50mL of 10xPBS was combined with 450mL of deionized water. 10mL of
glutathione sepharose beads was divided into four 15mL tubes. Then each tube was filled
to the top with the PBS solution. The tubes were placed in a centrifuge at 2000rpm. The
supernatant from each tube was dumped into a waste beaker while ensuring that none of
the beads were lost in the waste beaker. This cleaning procedure was repeated three
times. After the last round of cleaning, the protein from the large centrifuge was poured
in equal amounts into the four tubes filled with beads. The beads and protein were mixed
for 30 minutes.
At the end of the 30 minutes, the supernatant was poured into the waste beaker.
The beads were washed five times following the same cleaning procedure with PBS.
Then after the last washing, the beads were placed in a column. This column was
prepared by putting all the pieces together. Then in order to ensure that no air bubbles
were in the membrane of the column, a syringe filled with 10mL of PBS was connected
to the stopcock. Then the PBS was forced into the column using the syringe. 6mL of PBS
was left in the column and the beads were pipetted into the column.
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After this an elution buffer was made by first mixing 5mL of 50mM TRIS and
1M HCL (pH 8.0) with 95mL of deionized water. Afterwards, 0.307 grams of glutathione
was added to this solution. Five 15mL tubes were labeled 1-5. The column was drained
of all PBS into a waster beaker. Tube 1 was placed under the column in order to collect
the eluent that passed through the column after addition of 5mL of elution buffer. Tube 2
replaced Tube 1 and 10mL of elution buffer was added to the column. This was repeated
for Tube 3-5. It was expected that most of the protein would come out in Tube 2. In order
to test which tubes had protein in it, 200μL of a Bradford acid was poured into a small
tray. 20μL of the flow through was added to the acid. The acid would turn bright blue if
the solution contained protein. The tubes containing protein were then placed in the
fridge at 4°C overnight.
The next day an SDS-PAGE was ran to confirm the presence of the correct
protein. If it was correct then the proteins were concentrated and a Bradford Assay was
performed. Materials needed for this assay include a Protein Assay Dye Reagent
Concentrate (Bio-Rad, Cat. 500-006, 450mL) and 2mg/mL BSA standard. At the
beginning of this procedure, 10mL of 5x diluted working dye reagent was prepared and
2mg/mL BSA standard was diluted to 0.5mg/mL. A BSA standard concentration gradient
was formed using five 1.5mL vials. Table 1 was used to make the correct concentration
in the 1.5mL vials.
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BSA Standard Final Concentration
(microgram/tube)
0μg
Deionized Water
0.5mg/mL BSA

20µL
0μL

2μg

4μg

6μg

8μg

10μg

16μL

12μL

8μL

4μL

0μL

4μL

8μL

12μL

16μL

20μL

Table 1. BSA Standard Concentration preparation table.

Three samples containing the protein were created by mixing 8μL of the sample
with 72μL deionized water. 20μL of this solution was placed in three 1.5mL vials, and
then 1mL of the working reagent was added to each vial. The solution was mixed well
and allowed to sit for 10 minutes. A spectrophotometer was used to measure the
absorption at a wavelength of 595nm. Water was used as the blank sample.
Afterwards a plot was created to determine the concentration of protein. This
information was then used to determine the total amount of thrombin needed to cleave the
GST tags of the protein. The thrombin was added to the protein and left overnight. The
next day an SDS-PAGE was ran to see if the cleavage was successful.
While the SDS electrophoresis machine was running, a dialysis buffer was made
by measuring out 4mL of 500mM calcium chloride and 100mL 1M TRIS. This solution
was added to 1896mL of deionized water. The buffer was then placed in the fridge to
cool. A dialysis tube was washed using deionized water. The tube was checked for holes
by closing one end of the tube with one hand and allowing it to fill with water. This was
checked because if holes were present in the dialysis tube, the protein would be lost in the
dialysis buffer with no way of recovering the protein. If no holes were present a clamp
was placed at one end of the tube. The protein was pipetted into the dialysis tube and a
second clamp was placed at the top of the tube. The protein in the dialysis tube was then
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placed in 500mL of the dialysis buffer. The protein was left in dialysis for 48 hours with
the buffer being changed every 12 hours.
At the end of this dialysis period, the protein was purified by using the
same glutathione sepharose bead column. This time the purpose of the column was to
separate the GST tag from the protein. This column was cleaned using three 5mL
portions of glutathione. The beads were evenly distributed into 4 different 15mL tubes.
The tubes were filled with 1M TRIS pH 7.5 with calcium chloride buffer following the
same washing procedure that was used to originally clean the beads. The protein was then
added to the column in 1mL portions. 1.5mL vials were used to collect the flow through.
After each 1mL portion the solution was tested for protein using a 1x Bronstead Dye that
turns blue in the presence of protein. Once a portion of the flow through turns the dye
blue, a 15mL tube was placed under the column and the rest of the protein was added.
After collecting all of the protein an SDS-PAGE was run.
If impurities were still present in the sample, an anionic GSH column was used to
purify the protein. The beads for this column were prepared using the same washing
procedure, however only 3mL of beads were used. After washing the beads and placing
them in the column, the protein was added in 1mL portions. The flow through was
collected in 1.5mL portions. The Bradford dye was used to determine which ones had
protein. After adding all the protein to the column a salt concentration gradient column
was used to push the protein through the beads. The concentration gradient was prepared
according to Table 2.
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Salt Gradient
TRIS (pH7.5)
CaCl2

900μL

800μL

700μL 600μL

500μL

400μL

300μL

200μL

100μL

TRIS (pH7.5)
CaCl2 +NaCl

100μL

200μL

300μL 400μL

500μL

600μL

700μL

800μL

900μL

Table 2. Salt Gradient preparation guide.

The first salt buffer added to the column must contain the lowest salt
concentration. For one protein, ColGS3aSb(S997C), the concentration gradient was
performed with the highest concentration of salt first. This error was corrected by redoing
the dialysis by using 330mL of TRIS with calcium chloride buffer. The dialysis period
was 6 hours, while changing the buffer every 3 hours. Once the dialysis period was
finished the GSH column was used again. The protein was collected following the same
procedure as above while ensuring to perform the concentration gradient the proper way.
After collecting all these samples the vials were placed in the fridge and left overnight.
An SDS-PAGE analysis was performed the next day to confirm that the
purification columns worked. If the impurities were low enough the concentration of the
protein was determined by performing a BCA assay, using the BCA assay reagent kit by
ThermoScientific. In order to perform a BCA assay, a water bath was prepared at 60°C
and a working reagent was prepared by mixing a 50:1 ratio of Reagent A and Reagent B
from the kit. About 5 mL of this solution was needed for one person. The 2mg/mL BSA
standard was diluted with deionized water to get 0.25mg/mL BSA. Table 3, was used to
prepare the BSA standards.
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Deionized Water
0.25mg/mL BSA

BSA Standard (microgram/tube)
0μg
1μg
2μg
3μg
4μg
20μL 16μL 12μL
8μL
4μL
0μL
4μL
8μL
12μL 16μL

5μg
0μL
20μL

Table 3. BSA Standards.

Three samples of protein were created by mixing 8μL of the sample with 72μL
deionized water. 20μL of this solution was placed in three 1.5mL vials and then 40μL of
the working reagent was added to each sample including the BSA Standards. The vials
were mixed and then placed in the water bath for thirty minutes. At the end of thirty
minutes, the vials were placed in tap water to cool down for five minutes. The
spectrometer was used at a wavelength of 562nm, while water was used for the blank.
The readings were plotted and the concentration was determined. After determining the
concentration, the protein was placed in vials and placed in the freezer in order to be sent
back to the University of Arkansas.
C. Crosslinking Experiments
After returning to the University of Arkansas, ColGS3aS3b(S997C) became the
focus of crosslinking experiments. In order to ensure that the protein did bind to collagen,
a collagen binding assay was performed by Mary Kate Tucker. During this time, attempts
were made to attach crosslinkkers, such as APDP and PEAS, to the introduced cysteine
mutation. This was done by following the procedure performed by Keisuke with
ColGS3b(S997C). The first step of this protocol involves reducing the disulfide bonds in
the protein. A 1.5mL vial was prepared containing ~0.5mg/mL mutant CBD, 10μL 0.5 M
DTT (final concentration 10mM), and 12.5μL 0.2 M EDTA (final concentration 0.5mM).
PBS was added to bring the total volume to 500μL. The DTT was prepared by mixing
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100μL deionized water with 8mg DTT. The solution was incubated on ice for 30 minutes.
During the incubation time a PBS/EDTA dialysis buffer was created by adding 40mL
0.5M PB (pH 7.4), 44mL of 20% NaCl, and 5mL 0.2M EDTA. The total volume of the
solution was brought up to 1L using deionized water. The incubated solution was then
placed into dialysis devices (2 with 250μL of solution). The devices were placed in
500mL PBS/EDTA dialysis buffer and dialyzed for at least 5 hours at 4°C. At the end of
this time period, the dialysis buffer was changed and the solution was dialyzed overnight
(for at least five hours).
The next day, the crosslinker was introduced to the R+ mutant. Before this
occurred 20μL of R+ mutant was placed in a vial and then left in the freezer to be
analyzed by SDS-PAGE at the end of the crosslinking experiment. A separate vial
containing 500μL Mutant (R+), 425μL PBS, 25μL 0.2M EDTA, and 50μL 10mM
crosslinker was mixed. This solution was incubated for three hours at room temperature
in the dark. After this step, the protein must have limited light exposure. The crosslinker
is photoreactive, and therefore, too much light exposure could affect the experiment.
During the three hour incubation time, two dialysis buffers were created.
The first dialysis buffer was a HEPES buffer without calcium. This buffer was
created by mixing 40mL of 0.5M HEPES (pH7.5), 44mL of sodium chloride, and enough
deionized water to make the final volume 1L. The second buffer was a HEPES buffer
with calcium. This buffer was created the same way as the first buffer with the addition
of 1mL of 1M calcium chloride. The solution was then centrifuged at 13,500rpm for 10
minutes in order to collect the extra APDP. The supernatant was then placed in 3 dialysis
devices, which were then placed in the 1L of HEPES buffer without calcium. The
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solution was dialyzed in the dark cold room at 4°C for at least five hours. The devices
were then transferred to a beaker containing 1L of HEPES buffer with calcium for at least
five hours at 4°C in the dark.
The next step involves concentrating the cross-linked protein in order to analyze if
the crosslinker attached to the cysteine mutation. The protein was spun at 6000rpm for
around two and a half hours until the final volume was between 50-100μL. The
concentration of the protein was analyzed by UV-Vis spectrometer. After determining the
concentration, the protein was analyzed by SDS-PAGE. In order to perform this analysis,
samples were made from the wild type, wild type with mutation, R+ protein, cross-linked
protein before UV radiation, and cross-linked protein after UV radiation. The final
concentration of analyzed proteins was 3μg. In order to prepare the cross-linked sample
after UV radiation the UV light was turned on and left to warm up for 15 minutes. Then,
the protein was placed under the UV light for 30minutes. 4XBuffer and 4XBPB were
added to all the samples, which were then heated at 98°C for 4 minutes before applying
to a 12% SDS -PAGE.
After getting APDP or PEAS to successfully attach, the cross-linked protein was
used in a crosslinking assay with rattus type I collagen or bovine type III collagen. Two
vials were prepared containing 12.5μL of 2mg/mL collagen, ~0.1mg/mL cross-linked
mutant, and 12.5μL 2x Binding Buffer. Before mixing, 1x Binding Buffer was added to
both vials to make the total volume 50μL. The solutions were then incubated at room
temperature for 30 minutes. During this time, the UV light was turned on, in order to
warm up the bulb. Then, one vial was irradiated for 30 minutes.
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During this time, two sample buffers were made. One sample buffer without DTT
was prepared by mixing 60μL 2xBuffer, 3μL 4xBPB and 57μL deionized water. The
other buffer was prepared using 60μL 2xBuffer, 3μL 4xBPB 12μL DTT and 45μL
deionized water. At the end of the radiation time, both of the original vials were split into
25μL aliquots, for a total of four aliquots. The vials were labeled UV+ with DTT, UV+
with no DTT, UV- with DTT, and UV- with no DTT. For each vial, 25μL of appropriate
sample buffer was added. The two vials labeled “with DTT” received the sample buffer
with DTT, while the other two vials received sample buffer without DTT. After adding
the sample buffers, the samples were heated at 98°C for 4 minutes. 30μL of each sample
was loaded into the wells of a 7.5% SDS-PAGE by placing a marker (first lane), UVwith no DTT (second lane), UV+ with no DTT (third lane), a marker (fourth lane), UVwith DTT (fifth lane), and UV+ with DTT (sixth lane).
After confirming crosslinking with collagen, a fibril formation assay was
performed. This was performed for two reasons. One reason was to ensure that the
incubation time period was long enough for fibril formation of collagen. Another reason
was to observe the effects that APDP attached ColGS3aS3b(S997C) had on collagen
fibril formation. In order to perform this experiment a plate with small wells was used.
On this plate, 8 different wells were used. A 2x Binding Buffer was prepared which
consists of 40mM HEPES (pH 7.5), 0.3M NaCl and 2mM Calcium Chloride. Wells were
first prepared with water and buffer in Dr. Sakon’s laboratory, then after walking to Dr.
Strieglers laboratory, collagen and APDP attached CBD were added. In the first well
150μL of 2x Binding Buffer was added to 150μL deionized water. The second well was a
collagen control, in which 150μL 2x Binding Buffer, 75μL deionized water, and 75μL
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rattus type I collagen (2mg/mL) was added to the well. The third well contained 0.1:1
ratio of APDP attached CBD to collagen. Therefore 0.7μL APDP attached CBD
(2.68mg/mL), 74.3μL deionized water, 75μL rattus type I collagen (2mg/mL) and 150μL
2x Binding Buffer was added to the well. The fourth well consisted of a 0.2:1 ratio or
1.4μL APDP attached CBD (2.68mg/mL), 73.6μL deionized water, 75μL rattus type I
collagen (2mg/mL) and 150μL 2x Binding Buffer. The fifth well (0.3:1 ratio) was
prepared with 2.1μL APDP attached CBD (2.68mg/mL), 72.9μL deionized water, 75μL
rattus type I collagen (2mg/mL) and 150μL 2x Binding Buffer. The sixth well (0.4:1
ratio) was prepared with 2.8μL APDP attached CBD (2.68mg/mL), 72.2μL deionized
water, 75μL rattus type I collagen (2mg/mL) and 150μL 2x Binding Buffer. The seventh
well (0.5:1 ratio) was prepared with 3.5μL APDP attached CBD (2.68mg/mL), 71.5μL
deionized water, 75μL rattus type I collagen (2mg/mL) and 150μL 2x Binding Buffer.
The eighth well (1:1 ratio) was prepared with 7μL APDP attached CBD (2.68mg/mL),
68μL deionized water, 75μL rattus type I collagen (2mg/mL) and 150μL 2x Binding
Buffer. The machine was ran at 37°C for 3 hours. After obtaining the data, an excel
spreadsheet was created. This experiment was performed two times because the first
experiment produced unclean results.
After confirming that a 30 minute incubation period was sufficient time for fibril
formation, the crosslinking experiment was analyzed by 2-D diagonal electrophoresis. A
vial was prepared containing 6.25μL 2mg/mL collagen, ~0.1mg/mL cross-linked mutant,
and 6.25μL 2x Binding Buffer. Before mixing, 1x Binding Buffer was added to make the
total volume 25μL. After irradiating the sample for 30 minutes, 25μL of sample buffer
without DTT was added and the sample was heated at 98°C for 4 minutes. The sample
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was applied to a single well in a 5% SDS-PAGE with marker on both sides. After
running the gel, a knife was used to cut out the lane containing the sample. The lane was
transferred to 20mL a solution of sample buffer which was prepared by mixing 10mL of
2x Sample Buffer, 0.5mL 4xBPB, 1mL 1M DTT, and 8.5mL deionized water. 2x Sample
buffer was prepared by mixing 4g SDS and 15g glycerol with 12.5mL of 1 M Tris pH
6.8. The total volume of this 2x Sample buffer solution was brought up to 50mL using
deionized water. The lane was soaked in the sample buffer for 10 minutes. The gel piece
was then washed with 20mL of a TES buffer for 7 minutes for a total of three washes.
The gel piece was placed in 10mL TES with 10μL fluorescein, and kept in the dark for 20
minutes. From this point on all work was done in the dark, in order to ensure that
photoreactive crosslinker was not activated. The gel was then washed in a solution
containing 20mL TES and 200μL DTT for 7 minutes for a total of three washes. The gel
was then placed horizontally in the well space of a 5% gel. The gel was under
electrophoresis until a separate yellow band was visible on the SDS-PAGE. After running
the gel, a picture of the SDS-PAGE was taken using UV light to show the fluorescent
binding. Afterwards the gel was treated with Coomassie Blue or silver chloride stain.
If the crosslinking did occur then the samples from the crosslinking assay can be
mass produced and the bands representing the crosslinking can be cut of the SDS-PAGE
to be analyzed cleaved by trypsin digest and analyzed by LC-MS/MS (ESI mass
spectrometry).
The next crosslinker that was used was a biotin (MTS-BP-BIO) crosslinker. This
crosslinker was attached to ColGS3aS3b(S997C) using the same experimental procedure
as for the APDP and PEAS crosslinker. After analysis by SDS-PAGE to see what the
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crosslinking experiment produced, the protein was purified using streptavidin magnetic
beads. In order to perform this experiment, 50μL of these beads (0.5mg) were placed in a
1.5mL vial. The beads were then placed in a magnetic stand that was included when
purchasing the crosslinker. The beads congregated on the wall near the magnet until the
solution was clear. 1mg of beads allows ~3500pmol biotynylated binding so in order to
ensure binding to the streptavidin beads a sample was prepared. Calculations were
performed in order to convert the concentration to picomols. It was determined that the
concentration of protein needed to be less than 1750pmol because 0.5mg of beads was
used.
20μL of the prepared sample was added to 280μL of washing/binding buffer. The
washing/binding buffer was made by using 5μL of 100% Tween and 4.995mL of 25mM
TRIS, 0.15M NaCl (pH 7.2). The supernatant from the vial with the beads was then
carefully discarded using a pipette, ensuring that no beads were taken out with the
supernatant. After taking out the supernatant, 1mL of this buffer was added to the beads.
This must be done in a timely manner in order to ensure that the beads don’t dry out. The
beads were mixed by flicking the vial. The vial was then placed back into the magnetic
stand to allow separation from the supernatant. The wash was removed from the magnetic
beads and the 300μL sample was added to the beads. The beads and protein sample were
incubated for an hour at room temperature. The beads were mixed every five minutes to
ensure that the beads were in solution at all times.
Once the incubation period was up a magnetic stand was used to collect the beads.
The supernatant was removed and kept in a vial for analysis. The supernatant should
contain protein that was not attached to biotin. The beads were then washed three times
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with 300μL washing/binding solution while discarding the supernatant after each wash.
The biotin attached protein was then eluted off the beads using 100μL of 0.1M Glycine
(pH 2). The beads were incubated for 5 minutes at room temperature. The solution was
then taken out of the beads and placed in a vial. The beads can be reused, so 300μL
washing/binding buffer was added to the beads and they were stored in the refrigerator.
The solution containing biotin attached protein was concentrated and the final
concentration was determined using UV–Vis spectroscopy.
After one experiment with biotin it became clear that the biotin did not attach to
the cysteine mutation of collagen binding domain and several unexpected bands were
seen. The sample was sent to mass spectroscopy analysis. It was suspected that somehow
the protein was cleaved and in order to rule out a protease the biotin experiment was
repeated using a protease inhibitor cocktail.
Another crosslinker used was fluorescein-5-maleimide dissolved in DMSO
(fluorescein). The same crosslinking protocol was used except for the concentration of
crosslinker was changed to a 25 molar excess of fluorescein. After calculations, it was
determined that 2.4μL of fluorescein was needed for tandem CBD. After running the
SDS-PAGE, the gel was observed under UV light to observe the distribution of tandem
CBD. The crosslinker attached CBD was then analyzed using rattus type I collagen to see
if it would crosslink to collagen. The sample was analyzed by SDS-PAGE analysis.
After analysis, the fluorescein attached tandem CBD was purified using size
exclusion chromatography. In order to this 2g of G10-sephadex beads was weighed out.
The beads were added to 6mL, pH 7.5 HEPES, and 150mM NaCl (Buffer 1). The beads
were allowed to swell for 3 hours at room temperature. The beads were then decanted out
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of the column. The bead bed was allowed to settle and the column was drained. After
draining the column, 5mL of Buffer 1 was allowed to drain through the column. The
sample was concentrated (>200uL) and added to the column. Buffer 1 was applied to the
column in 1mL aliquots until there was a clear separation between layers. As the bottom
layer started to reach the stopcock 250uL samples were collected. The vials were marked
in the order that they were collected. The samples were collected until relatively clear,
which results in about 13-20 total samples collected. The absorbance was checked at
280nm for the most concentrated protein samples, which were expected to be the first
three or four vials collected. The most concentrated samples were pooled together and
were concentrated to approximately 100μL. The beads are reusable so they were cleaned
using 10mL of 0.2% NaOH. 10mL of Buffer 1 was added to the beads to ensure that the
beads remained moist for the next use. After concentrating the newly purified protein a
crosslinking assay was ran in order to observe the crosslinking of this protein with rattus
type I collagen.
D. Remodeling Collagen Experiments
For the remodeling collagen experiments using pancreatic cancer cells,
fluorescein attached ColGS3aS3b(S997C) and fluorescein attached ColGS3aS3b(Y996A,
S997C) were produced following the above crosslinking method. After confirming
crosslinker attachment, the proteins were taken to Dr. Yuchun Du laboratory at the
University of Arkansas. Tandem CBDs were placed in a freezer until cancer cells were
grown. In this laboratory, MiaPaCa2 cancer cells were grown in DMEM medium with
10%FBS and 1%Pen Strep. These cells were grown until they showed a loss of contact
inhibition at 37°C and 5% carbon dioxide. At this point, 50ng/μL (final concentration) of
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fluorescent CBD was added and incubated overnight at 37°C. The cells were then stained
with DAPI stain, which stains the nucleus. Images were taken with an Axio.Vision
microscope.
E. LC-MS/MS (ESI mass spectrometry)
Bruker Amazon-SL with captive-spray source coupled to a quadrupole ion trap
mass spectrometer was used for MS/MS work. Agilent 1200 series HPLC with a nano
pump was used for the chromatographic separation using a C18 revers phase nano
column. This column has a dimensions of 0.1 x150 mm and contains particles with a size
of 5 micron particle and 300 Ao pore size. A Water/ACN gradient was used to elute the
compounds at a flow rate of 1.6 μl/min.
V.

Results
A. Mutagenesis Projects and Protein Production
Figure 12. GST tagged ColGS3aS3b after GSH
purification. (06/06/2013)
Confirmation of GST tagged ColGS3aS3b, after
purification using the glutathione sepharose beads column.
Lane 1, molecular weight marker (94, 67, 43, 30, 20.1, 14.4
kDa). Lane 2-8, protein for fellow lab partner (i.e. not
applicable for this experiment). Lane 9-14, represents the

different vials that were used to collect the eluted purified protein. The molecular weight of GST is
26.9kDa and the molecular weight of ColGS3aS3b is 27.055kDa [11]. Therefore, the 55kDa band shows
that the correct protein was produced.
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Figure 13. BSA Assay plot for ColGS3aS3b. (06/06/2013)
Plot of Concentration vs Absorption showed that there was
approximately 11mL of 3.1μg/μL ColGS3aS3b obtain after the
first round of purification using GSH purification column. Using
this information, it was determined that 170.5 units of Thrombin
needed to be added in order to cleave the GST tag off of Col
GS3aS3b.
Figure 14. Cleavage of GST tagged ColGS3aS3b. (06/07/2013)
Confirmation of cleavage after adding thrombin to ColGS3aS3b. Lane 1, molecular
weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2, not applicable to this
experiment. Lane 3, cleaved ColGS3aS3b with GST tag still present. Even though
the molecular weight of ColGS3aS3b is only 27.055kDa, this protein shows up as a
38KDa band on SDS-PAGE [11]. The molecular weight of GST is 26.9kDa but is represented by a 28kDa
band on SDS-PAGE. Therefore the presence of the 28kDa band shows that the GST tag was cleaved off the
protein. The presence of the 38kDa band confirms that ColGS3aS3b was produced.
Figure 15. ColGS3aS3b after GSH purification. (06/10/2013)
Second round of GSH column purification did not get rid of all the impurities in the
sample. Lane 1, molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2-4,
shows the four vials that were collected during purification. The presence of the 38kDa
band shows that ColGS3aS3b is present in the sample. The high concentration of
smaller molecular weight bands indication that an ionic exchange purification column
using a salt concentration gradient needed to be performed.
Figure 16. ColGS3aS3b after purification using ionic exchange
column. (06/10/2013)
Results show that salt concentration gradient significantly reduced
the amount of impurities in the samples. Lane 1, molecular weight
marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2-13, shows the vials
that were collected during purification. The presence of the 38kDa
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confirms that our desired protein was still in the collected samples and the protein had a relatively small
amount of impurities. Therefore, a BCA assay was ran in order to determine the amount of protein in the
collected sample.
Figure 17. BCA Assay plot for ColGS3aS3b. (06/12/2013)
Plot of Concentration vs Absorption showed that there was
approximately 1.625mg/mL of ColGS3aS3b obtained in each vial.

Figure 18. Forward and Reverse plasmids for ColGS3aS3b(Y996A, S997C) after first
PCR reaction. (06/19/2013)
First PCR reaction appears to be successful at making the correct base pair plasmid. Lane 1,
molecular weight marker (19329, 7743, 6223, 4254, 3472, 2690, 1882, 1489, 925, 421, 74
base pairs). Lane 2, DNA strand created using 5’ primer, Reverse Primer, and E022 DNA
plasmid. Lane 3, DNA strand created using 3’ primer, Forward primer, and E022 DNA
plasmid. The presence of the 754 base pair band in lane 2 confirms that the correct base pair plasmid was
created. The 150 base pair band to indicate that the Forward primer was not visible in lane 3. 150 base pairs
is very small number of base pairs. It was assumed that the electrophoresis machine had run to long, which
allowed for the small plasmid to run off the page. There was mutual consensus to move on to the next PCR
reaction.
Figure 19. GST tagged ColGS3aS3b(S997C) after GSH purification.
(06/20/2013)
Confirmation that GST tagged ColGS3aS3b(S997C) was successfully produced
after confirming the sequence of Ryan Bauer’s stock E022. Lane 1, molecular
weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2-8, represents the different
vials that were used to collect the eluted purified protein. The molecular weight
of GST is 26.9kDa and the molecular weight of ColGS3aS3b is 27.055kDa [11]. Therefore, the 55kDa
band shows that the correct protein was produced.
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Figure 20. Cleavage of GST tagged ColGS3aS3b(S997C). (06/24/2013)
Confirmation of cleavage after adding thrombin to ColGS3aS3b(S997C). Lane 1, molecular
weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2, cleaved ColGS3aS3b with GST tag
still present. Even though the molecular weight of ColGS3aS3b is only 27.055kDa, this
protein shows up as a 38kDa band on SDS-PAGE [11]. The molecular weight of GST is
26.9kDa but is represented by a 28kDa band on SDS-PAGE. Therefore the presence of the
28kDa band shows that the GST tag was cleaved off the protein. The presence of the 38kDa
band confirms that ColGS3aS3b(S997C) was produced.
Figure 21. Fused DNA plasmid after second PCR reaction for
ColGS3aS3b(Y996A,S997C). (06/19/2013)
Confirmation of fusion between the forward and reverse primers made after first round of
PCR. Lane1, DNA molecular weight marker (19329, 7743, 6223, 4254, 3472, 2690,
1882, 1489, 925, 421, 74 base pairs). Lane 2, fused DNA plasmid. The presence of a 900
base pair band shows that the PCR reaction was successful in fusing the forward and reverse primers
Figure 22. BSA Assay plot for
ColGS3aS3b(S997C). (06/21/2013)
Plot of Concentration vs Absorption showed that
there was approximately 13.5mL of 2.25μg/μL
ColGS3aS3b(S997C) obtain after the first round of
purification using a GSH purification column. Using
this information, it was determined that 151.875
units of Thrombin needed to be added in order to
cleave the GST tag off of Col GS3aS3b(S997C).
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Figure 23. ColGS3aS3b(S997C) after GSH purification.
(06/28/2013)
Second round of GSH column purification did not get rid of all the
impurities in the sample. Lane 1, molecular weight marker (94, 67,
43, 30, 20.1, 14.4 kDa). Lane 2-9, shows the vials that were
collected during purification. The presence of the 38kDa band shows that ColGS3aS3b(S997C) is present
in the sample. In order to get an even purer sample, it was decided that an ionic exchange purification
column using a salt concentration gradient need to be performed.
Figure 24. ColGS3aS3b(S997C) after purification using ionic
exchange column. (06/28/2013)
Results indicate incorrect addition of salt concentration gradient.
Lane 1, molecular weight marker (94, 67, 43, 30, 20.1, 14.4
kDa). Lane 2-14, represents the different vials that were used to
collect the eluted purified protein. Lane 15, molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane
16-17, represents the different vials that were used to collect the eluted purified protein. In order for a salt
concentration gradient to work the protein is supposed to be eluted slowly using slowly increasing
concentration of salt. In this experiment the highest concentration of salt was used first which is incorrect.
Figure 25. ColGS3aS3b(S997C) after purification
using ionic exchange column. (06/29/2013)
Results show that salt concentration gradient
significantly reduced the amount of impurities in the
sample. Lane 1, molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2-15, shows the vials that
were collected during purification. Lane 16, molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa).
Lane 7-23, shows a portion of the samples that were collected during purification. The presence of the
38kDa confirms that our desired protein was still in the collected samples and the protein had a relatively
small amount of impurities. Therefore, a BCA assay was ran in order to determine the amount of protein in
the collected sample.
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Figure 26. ColGS3aS3b(Y996A,S997C) DNA plasmid from DH5α colonies for
sequencing. (06/29/2013)
After cleavage using XhoI and EcoRI-HF, it appears that Colony #1 contains the correct
DNA plasmid. Lane 1, DNA molecular weight marker (19329, 7743, 6223, 4254, 3472, 2690,
1882, 1489, 925, 421, 74 base pairs). Lane 2, Colony #1 DNA plasmid. Lane 3, Colony #2
DNA plasmid. After cleavage, Colony #1 contains two DNA fragments with a molecular weight of
approximately 754 and 150 base pairs, which confirms that the DNA plasmid could contain the correct
mutation. After cleavage, Colony #2 only has one band and therefore it does not have the correct DNA
plasmid.
Figure 27. BCA Assay Plot for ColGS3aS3b(S997C).
(07/01/2013)
Plot of Concentration vs Absorption showed that there was
approximately 1.4mg/mL of ColGS3aS3b(S997C) obtained
in each vial.

Figure 28. BCA Assay Plot for ColGS3aS3b(S997C).
(07/01/2013)
Plot of Concentration vs Absorption showed that there was
approximately 5.2mg/mL of ColGS3aS3b(S997C) obtained
in each vial.
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Figure 29. Forward and Reverse plasmids for ColGS3b(Y996A, S997C) after first PCR
reaction. (07/02/2013)
First PCR reaction appears to be successful at -making the correct base pair plasmid. Lane 1,
molecular weight marker (19329, 7743, 6223, 4254, 3472, 2690, 1882, 1489, 925, 421, 74
base pairs). Lane 2, DNA strand created using 5’ primer, Reverse Primer, and E022 DNA
plasmid. Lane 3, DNA strand created using 3’ primer, Forward primer, and E022 DNA
plasmid. The presence of the 454 base pair band in lane 2 confirms that the correct base pair plasmid was
created. The 150 base pair band that would indicate the Forward primer was barely visible at the bottom of
lane 3.
Figure 30. Fused DNA plasmid after second PCR reaction for
ColGS3aS3b(Y996A,S997C). (06/19/2013)
Confirmation of fusion between the forward and reverse primers made after first round of
PCR. Lane1, DNA molecular weight marker (19329, 7743, 6223, 4254, 3472, 2690, 1882,
1489, 925, 421, 74 base pairs). Lane 2, fused DNA plasmid. The presence of a 604 base pair
band shows that the PCR reaction was successful in fusing the forward and reverse primers.

Figure 31. Colony PCR for ColS3b(Y996A,S997C). (07/05/2013)
Colony PCR shows that three DH5α colonies contain correct DNA
plasmids. Lane1, DNA molecular weight marker (19329, 7743,
6223, 4254, 3472, 2690, 1882, 1489, 925, 421, 74 base pairs). Lane
2, Colony #1. Lane 3, Colony #2. Lane 4, Colony #3. Lane 5,
Colony #4. Lane 6, Colony #5. Lane 7, Colony #6. Lane 8, Colony
#7. Lane 9, water control. Colony # 1, 3, and 5 show two correct
fragments with molecular weight 150 and 454 base pairs. Inoculated tubes with LB broth for all three
colonies.
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Figure 32. ColGS3b(Y996A,S997C) DNA plasmid from DH5α colonies for
sequencing. (07/05/2013)
Incorrect cleavage plasmid #3 and #5 using XhoI and EcoRI-HF, however plasmids were
still sequenced because protein had already been prepared. Lane1, DNA molecular weight
marker (19329, 7743, 6223, 4254, 3472, 2690, 1882, 1489, 925, 421, 74 base pairs). Lane
2, Plasmid #3 after cleavage. Lane 3, Plasmid #5 after cleavage. Even though cleavage is
not obvious, after sequencing it became clear that Plasmid #3 and #5 contained the
correct DNA sequences.
Figure 33. Colony PCR for ColS3aS3b(Y996A,S997C). (07/11/2013)
Colony PCR shows that three DH5α colonies contain the correct plasmid.
Lane1, DNA molecular weight marker (19329, 7743, 6223, 4254, 3472, 2690,
1882, 1489, 925, 421, 74 base pairs). Lane 2, water control. Lane 3, Colony #7
from master plate. Lane 4, Colony #6 from master plate. Lane 5, Colony #5
from master plate. Lane 6, Colony #4 from master plate. Lane 7, Colony #3
from master plate. Lane 8, Colony #2 from master plate. Colonies 2, 3, and 4 were used to inoculate broth
in order to obtain DNA plasmid.
Figure 34. GST tagged ColGS3aS3b(Y996A, S997C) after
GSH purification. (07/16/2013)
Confirmation that GST tagged ColGS3aS3b(Y996A, S997C) was
successfully produced. Lane 1, molecular weight marker (94, 67,
43, 30, 20.1, 14.4 kDa). Lane 2-8, represents the different vials
that were used to collect the eluted purified protein. The
molecular weight of GST is 26.9kDa and the molecular weight of ColGS3aS3b is 27.055 kDa [11].
Therefore, the 55kDa band shows that the correct protein was produced.
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Figure 35. BSA Assay Plot for ColGS3aS3b(Y996A/S997C).
(07/16/2013)
Plot of Concentration vs Absorption showed that there was
approximately 14.5mL of 5μg/μL
ColGS3aS3b(Y996A,S997C) obtain after the first round of
purification using a GSH purification column. Using this
information, it was determined that 179.63 units of Thrombin needed to be added in order to cleave the
GST tag off of Col GS3aS3b(Y996A,S997C).
Figure 36. Forward and Reverse plasmids for ColGS3aS3b(Y994A,S997C) after first
PCR reaction. (07/16/2013)
First PCR reaction appears to be successful at making the correct base pair plasmid. Lane 1,
molecular weight marker (19329, 7743, 6223, 4254, 3472, 2690, 1882, 1489, 925, 421, 74
base pairs). Lane 2, DNA strand created using 5’ primer, Reverse Primer, and E022 DNA
plasmid. Lane 3, DNA strand created using 3’ primer, Forward primer, and E022 DNA
plasmid. The presence of the 150 base pair band that would indicate the Forward primer was
barely visible at the bottom of lane 2, confirms that the correct base pair plasmid was created. The 754 base
pair band confirms that the correct base pair plasmid was created in lane 3.
Figure 37. Fused DNA plasmid after second PCR reaction for
ColGS3aS3b(Y994A,S997C). (07/17/2013)
Confirmation of fusion between the forward and reverse primers made after first round of
PCR. Lane 1, DNA molecular weight marker (19329, 7743, 6223, 4254, 3472, 2690, 1882,
1489, 925, 421, 74 base pairs). Lane 2, fused DNA plasmid. The presence of a 904 base pair
band shows that the PCR reaction was successful in fusing the forward and reverse primers.
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Figure 38. Cleavage of GST tagged ColGS3aS3b(Y996A, S997C). (07/17/2013)
Confirmation of cleavage after adding thrombin to ColGS3aS3b(Y996A, S997C). Lane
1, molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2, cleaved
ColGS3aS3b with GST tag still present. Even though the molecular weight of
ColGS3aS3b is only 27.055kDa, this protein shows up as a 38kDa band on SDS-PAGE
[11]. The molecular weight of GST is 26.9kDa but is represented by a 28kDa band on
SDS-PAGE. Therefore the presence of the 28kDa band shows that the GST tag was cleaved off the protein.
The presence of the 38kDa band confirms that ColGS3aS3b(Y996A, S997C) was produced.
Figure 39. Colony PCR for ColS3aS3b(Y996A,S997C). (07/19/2013)
Colony PCR shows that four DH5α colonies contain the correct plasmid.
Lane1, DNA molecular weight marker (19329, 7743, 6223, 4254, 3472,
2690, 1882, 1489, 925, 421, 74 base pairs). Lane 2, Colony #1 from
master plate. Lane 3, Colony #2 from master plate. Lane 4, Colony #3
from master plate. Lane 5, Colony #4 from master plate. Lane 6, Colony
#5 from master plate. Lane 7, Colony #6 from master plate. Lane 8, water control. Colonies 2 and 3 were
used to inoculate broth in order to obtain DNA plasmid.
Figure 40. ColGS3aS3b(Y996A, S997C) after GSH
purification. (07/20/2013)
Second round of GSH column purification did not get rid of all
the impurities in the sample. Lane 1-6, eluant captured while
using the purification column. Lane 7 and 8, molecular weight
marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 9-10, shows the vials that were collected during purification.
The presence of the 38kDa band shows that ColGS3aS3b(Y996A,S997C) is present in the sample. In order
to get an even purer sample, it was decided that an ionic exchange purification column using a salt
concentration gradient need to be performed.
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Figure 41. ColGS3aS3b(Y996A,
S997C) after purification using ionic
exchange column. (07/22/2013)
Results show that salt concentration
gradient significantly reduced the
amount of impurities in the sample. Lane 1-14, shows the vials that were collected during purification.
Lane 15, molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 16-29, shows the vials that were
collected during purification. Lane 30, molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). The
presence of the 38kDa confirms that our desired protein was still in the collected samples and the protein
had a relatively small amount of impurities. Therefore, a BCA assay was ran in order to determine the
amount of protein in the collected sample.
Figure 42. GST tagged ColGS3b(Y996A, S997C) after GSH
purification. (07/22/2013)
Confirmation that GST tagged ColGS3b(Y996A, S997C) was
successfully produced. Lane 1, molecular weight marker (94, 67,
43, 30, 20.1, 14.4 kDa). Lane 2-8, represents the different vials that
were used to collect the eluted purified protein. The molecular weight of GST is 26.9kDa and the molecular
weight of ColGS3b is 13.787kDa [11]. Therefore, the 29kDa band shows that the correct protein was
produced
Figure 43. BCA Assay Plot for
ColGS3aS3b(Y996A,S997C). (07/23/2013)
Plot of Concentration vs Absorption showed that there was
approximately 1.55mg/mL of ColGS3aS3b(Y996A,S997C)
obtained in each vial for a total of 9.3mg.
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Figure 44. BSA Assay Plot for
ColGS3b(Y996A/S997C). (07/23/2013)
Plot of Concentration vs Absorption showed that
there was approximately 29.7 of 3.3μg/μL for tube 1
and 23.5mL of 2.353μg/μL of
ColGS3b(Y996A,S997C) obtained after the first
round of purification using a GSH purification
column. Using this information, it was determined
that 148.5 units of Thrombin and 117.5 units of thrombin were needed for tube 1 and tube 2 respectively in
order to cleave the GST tag off of Col GS3b(Y996A,S997C)
Figure 45. Cleavage of GST tagged ColGS3b(Y996A, S997C). (07/24/2013)
Confirmation of cleavage after adding thrombin to ColGS3b(Y996A, S997C). Lane 1,
molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2, cleaved
ColGS3aS3b with GST tag still present. Even though the molecular weight of
ColGS3b is only 13.787kDa, this protein shows up as a 16.5kDa band on SDS-PAGE
[11]. The molecular weight of GST is 26.9kDa but is represented by a 28kDa band on
SDS-PAGE. Therefore the presence of the 28kDa band shows that the GST tag was
cleaved off the protein. The presence of the band at the bottom of the page confirms that ColGS3b(Y996A,
S997C) was produced.
Figure 46. GST tagged ColGS3a(S879C) after GSH
purification. (07/25/2013)
Confirmation that GST tagged ColGS3a(S879C) was successfully
produced. Lane 1, molecular weight marker (94, 67, 43, 30, 20.1,
14.4 kDa). Lane 2-8, represents the samples that were collected in
the different vials. The molecular weight of GST is 26.9kDa and the
molecular weight of ColGS3a is 14. 223kDa [11]. Therefore, the
43kDa band shows that the correct protein was produced.
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Figure 47. BSA Assay Plot for ColGS3a(S879C).
(07/26/2013)
Plot of Concentration vs Absorption showed that there
was approximately 21.15mL of 4.7μg/μL of
ColGS3a(S879C) obtained after the first round of
purification using a GSH purification column. Using this
information, it was determined that 105.75 units of Thrombin was needed in order to cleave the GST tag
off of ColGS3a(S879C).
Figure 48. ColGS3b(Y996A,S997C) DNA plasmid from DH5α colonies for sequencing.
(07/26/2013)
After cleavage using XhoI and EcoRI-HF, it appears that Colony #1 and Colony #2 contains
the correct DNA plasmid. Lane 1, DNA molecular weight marker (19329, 7743, 6223, 4254,
3472, 2690, 1882, 1489, 925, 421, 74 base pairs). Lane 2, Colony #1 DNA plasmid. Lane 3,
Colony #2 DNA plasmid. After cleavage, Colony #1 and #2 contains two DNA fragments
with a molecular weight of approximately 754 and 150 base pairs, which confirms that the DNA plasmid
could contain the correct mutation. After sequencing it was determined that they do contain the correct
sequences.
Figure 49. Cleavage of GST tagged ColGS3a(S879C). (07/30/2013)
Confirmation of cleavage after adding thrombin to ColGS3a(S879C). Lane 1, molecular
weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2, cleaved ColGS3a(S879C) with
GST tag still present. Even though the molecular weight of ColGS3a is only 14.223kDa,
this protein shows up as a 23kDa band on SDS-PAGE [11]. The molecular weight of GST
is 26.9kDa but is represented by a 28kDa band on SDS-PAGE. Therefore the presence of
the 28kDa band shows that the GST tag was cleaved off the protein. The presence of the
23kDa band at the bottom of the page confirms that ColGS3a(S879C) was produced.
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Figure 50. GST tagged ColGS3b(Y996A, S997C) after GSH
purification. (07/31/2013)
After losing the first batch of ColGS3b(Y996A,S997C) due to a hole in
the dialysis tube, reproduced protein confirms that GST tagged
ColGS3b(Y996A, S997C) was successfully produced again. Lane 1,
molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2-7,
represents the different vials that were used to collect the eluted purified protein. The molecular weight of
GST is 26.9kDa and the molecular weight of ColGS3b is 13.787kDa [11]. Therefore, the 29kDa band
shows that the correct protein was produced.
Figure 51. GST tagged ColGS3aS3b(S879C) after GSH
purification. (08/01/2013)
Confirmation that GST tagged ColGS3aS3b(S879C) was successfully
produced. Lane 1, molecular weight marker (94, 67, 43, 30, 20.1, 14.4
kDa). Lane 2-7, represents the different vials that were used to collect
the eluted purified protein. The molecular weight of GST is 26.9kDa and the molecular weight of
ColGS3aS3b is 27.055kDa [11]. Therefore, the 55kDa band shows that the correct protein was produced.
Figure 52. ColGS3a(S879C) after GSH purification.
(06/28/2013)
Second round of GSH column purification did not get rid
of all the impurities in the sample. Lane 1, molecular
weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 213, shows the vials that were collected during purification. The presence of the 23kDa band shows that
ColGS3a(S879C) is present in the sample.
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Figure 53. BSA Assay Plot for ColGS3b(Y996A,S997C).
(08/01/2013)
Plot of Concentration vs Absorption showed that there was
approximately 75mL of 11μg/μL of
ColGS3b(Y996A,S997C).obtained after the first round of
purification using a GSH purification column. Using this
information, it was determined that 165 units of Thrombin was needed in order to cleave the GST tag off of
ColGS3b(Y996A,S997C).
Figure 54. BCA Assay Plot for ColGS3a(S879C).
(08/02/2013)
Plot of Concentration vs Absorption showed that there was
approximately 1.55mg/mL of ColGS3a(S879C) obtained in
each vial for a total of 4.65mg.
Figure 55. Cleavage of GST tagged ColGS3aS3b(S879C). (08/02/2013)
Confirmation of cleavage after adding thrombin to ColGS3aS3b(S879C). Lane 1, molecular
weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2, cleaved ColGS3aS3b with GST tag
still present. Even though the molecular weight of ColGS3aS3b is only 27.055 kDa, this
protein shows up as a 38kDa band on SDS-PAGE [11]. The molecular weight of GST is
26.9kDa but is represented by a 28kDa band on SDS-PAGE. Therefore the presence of the
28kDa band shows that the GST tag was cleaved off the protein. The presence of the 38kDa
band confirms that ColGS3aS3b(S879C) was produced.
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Figure 56. ColGS3aS3b(S879C) after GSH purification.
(08/02/2013)
Second round of GSH column purification did not get rid of all the
impurities in the sample. Lane 1, molecular weight marker (94, 67,
43, 30, 20.1, 14.4 kDa. Lane 2- 8, sample of collected purified
protein. The presence of the 38kDa band shows that
ColGS3aS3b(S879C) is present in the sample. Vials 2, 3, 7 and 8 were pooled and concentrated down to
0.5mL using an Amicon Ultra 4 (10kDa c.o) device. These were then pooled with 4-6 for a total volume of
11.0mL with a final concentration of 1.08mg/mL.
Figure 57. BCA Assay Plot for ColGS3aS3b(S879C). (08/02/2013)
Plot of Concentration vs Absorption showed that there was
approximately 1.08 mg/mL of ColGS3a(S879C) obtained in each vial
for a total of 11.9mg.

Figure 58. Cleavage of GST tagged ColGS3b(Y996A, S997C). (08/02/2013)
Confirmation of cleavage after adding thrombin to ColGS3b(Y996A, S997C). Lane 1,
molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2, cleaved ColGS3aS3b with
GST tag still present. Even though the molecular weight of ColGS3b is only 13.787kDa, this
protein shows up as a 16.5kDa band on SDS-PAGE [11] . The molecular weight of GST is
26.9kDa but is represented by a 28kDa band on SDS-PAGE. Therefore the presence of the
28kDa band shows that the GST tag was cleaved off the protein. The presence of the band at the bottom of
the page confirms that ColGS3b(Y996A, S997C) was produced.
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Figure 59. ColGS3b(Y996A, S997C) after
purification using ionic exchange column.
(08/02/2013) Results show that salt concentration
gradient significantly reduced the amount of
impurities in the sample. Lane 1, molecular weight
marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 2-7, sample of collected protein purified without salt
gradient. Lane 8, molecular weight marker (94, 67, 43, 30, 20.1, 14.4 kDa). Lane 9-18, samples of protein
collected with salt gradient. The presence of the 16.5kDa confirms that our desired protein was still in the
collected samples and the protein had a relatively small amount of impurities. Therefore, a BCA assay was
ran in order to determine the amount of protein in the collected sample.

Figure 60. BCA Assay Plot for ColGS3b(Y996A,S997C).
(08/02/2013)
Plot of Concentration vs Absorption showed that there was
approximately 3.97mg/mL of ColGS3b(Y996A,S997C) obtained in
each vial for a total of 35.3mg.

B. Crosslinking and Remodelling Collagen Experiments
Figure 61. ColGS3aS3b(S997C) +APDP (10/2/13)
Confirmation of attachment of APDP to ColGS3aS3b(S997C). Lane 1, Col
GS3aS3b(S997C). Lane 2, ColGS3aS3b(S997C) with APDP crosslinker after no
UV radiation. Lane 3, ColGS3aS3b(S997C) reacted with APDP crosslinker after
UV radiation. Lane 4, molecular weight marker (175, 80, 58, 46, 30, 25,17 kDa).
The apparent molecular weight of ColGS3aS3b(S997C) is 32kDa and 64kDa,
because it forms intermolecular disulfide bridge (lane 1). Reaction with APDP in
the presence of DTT prevented the intermolecular disulfide bridge formation and allowed for crosslinker
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attachment. After crosslinker attachment the disulfide bridge cannot be formed until exposed to UV (lane
2). UV exposure using light source for 30 min triggered intermolecular crosslinking occurred and is shown
by the 64kDa band (lane 3).
Figure 62. ColGS3aS3b(S997C) + Biotin (10/23/13)
Confirmation of attachment of biotin to
ColGS3aS3b(S997C). Lane 1, molecular weight marker
(175, 80, 58, 46, 30, 25,17 kDa). Lane 2, ColGS3aS3b.
Lane 3, ColGS3aS3b(S997C). Lane 4, reduced
ColGS3aS3b(S997C). Lane 5, ColGS3aS3b(S997C) with
biotin after no UV radiation. Lane 6, ColGS3aS3b(S997C)
with biotin after UV radiation. Lane 7, molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa). The
apparent molecular weight of wildtype ColGS3aS3b is 32kDa (lane 2). The apparent molecular weight of
ColGS3aS3b(S997C) is 32kDa and 64kDa, because it forms intermolecular disulfide bridge (lane
3). Introducing DTT to ColGS3aS3b prevented the intermolecular disulfide bridge formation (lane 4).
After crosslinker attachment the disulfide bridge cannot be formed until exposed to UV (lane 5). UV
exposure using light source for 30 min triggered intermolecular crosslinking occurred and is shown by the
64kDa band (lane 6).
Figure 63. ColGS3aS3b(S997C) + Biotin after Avidin purification
(10/26/13)
Results showing failed attempt at purification of biotin crosslinked
ColGS3aS3b(S997C). Lane 1, molecular weight marker (175, 80, 58, 46, 30, 25,
17 kDa). Lane 2, Col G S3aS3b. Lane 3, ColGS3aS3b(S997C). Lane 4,
ColGS3aS3b(S997C) + biotin before streptavidin beads without UV light. Lane 5, supernatant of all
protein not attached to Biotin. Lane 6, ColGS3aS3b(S997C) with biotin after elution from streptavidin
beads. Lane 7, molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa). The apparent molecular weight
of wildtype ColGS3aS3b is 32kDa (lane 2). The apparent molecular weight of ColGS3aS3b(S997C) is 32
and 64kDa, because it forms intermolecular disulfide bridge (lane 3). Still apparent in the unpurified
sample are unexplained lower molecular weight bands (lane 4). After addition to streptavidin beads it
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becomes clear that the lower molecular weight bands were not attached to biotin (lane 5). Elution of biotin
from the streptavidin beads shows that the crosslinking was not successful because of the lack of any bands
(lane 6).
Figure 64. ColGS3aS3b(S997C) + Biotin (4hour and 5 hour
incubation, 11/6/13)
Results from increasing incubation time, in an attempt to increase
amount of attached biotin to ColGS3aS3b(S997C). Lane 1,
molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa). Lane 2, ColGS3aS3b. Lane 3,
ColGS3aS3b(S997C). Lane 4, reduced ColGS3aS3b(S997C). Lane 5, ColGS3aS3b(S997C) with biotin
after a four hour incubation time and no UV radiation. Lane 6, ColGS3aS3b(S997C) with biotin after a four
hour incubation time and UV radiation. Lane 7, reduced ColGS3aS3b(S997C). Lane 8,
ColGS3aS3b(S997C) with biotin after a five hour incubation time and no UV radiation. Lane 9,
ColGS3aS3b(S997C) with biotin after a five hour incubation time and UV radiation. Lane 10, molecular
weight marker (175, 80, 58, 46, 30, 25,17 kDa). The apparent molecular weight of wildtype ColGS3aS3b is
32kDa (lane 2). The apparent molecular weight of ColGS3aS3b(S997C) is 32kDa and 64kDa, because it
forms intermolecular disulfide bridge (lane 3). Introducing DTT to ColGS3aS3b prevented the
intermolecular disulfide bridge formation (lane 4 and 7). After UV exposure for 30 minutes, it becomes
apparent that biotin did not attach for the four and five hour incubation time periods because of the absence
of 64kDa bands (lane 6 and 9). The slightly higher masses of 33kDa and the lower molecular weight bands
cause concern about the mechanism of crosslinking (lane 5, 6, 8, and 9).
Figure 65. ColGS3aS3b(S997C) + Biotin (double concentration,
11/6/13)
Results from increasing the concentration of mutant CBD to increase
amount of contact with biotin to ColGS3aS3b(S997C). Lane 1,
molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa). Lane 2,
ColGS3aS3b. Lane 3, ColGS3aS3b(S997C). Lane 4, reduced
ColGS3aS3b(S997C). Lane 5, ColGS3aS3b(S997C) with biotin after no UV radiation. Lane 6,
ColGS3aS3b(S997C) with biotin after UV radiation. Lane 7, molecular weight marker (175, 80, 58, 46, 30,
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25, 17 kDa). The apparent molecular weight of wild type ColGS3aS3b is 32kDa (lane 2). The apparent
molecular weight of ColGS3aS3b(S997C) is 32 and 64 kDa, because it forms intermolecular disulfide
bridge (lane 3). Introducing DTT to ColGS3aS3b prevented the intermolecular disulfide bridge formation
(lane 4). After UV exposure, it becomes apparent that biotin did not attach by observing the lack of 64kDa
molecular weight bands (lane 6). The slightly higher 33kDa band and the lower molecular weight bands
cause concern about the mechanism of crosslinking (lane 5 and 6). To get a better understanding of what
the bands represent, gel pieces from lane 6 were analyzed by mass spectrometry (see figure 7).
Figure 66. ColGS3aS3b(S997C) + Biotin (double concentration) after
Avidin Bead purification (11/27/13)
Results showing failed attempt at purification of Biotin attached Col G
S3aS3b (S997C). Lane 1, molecular weight marker (175, 80, 58, 46, 30,
25, 17 kDa). Lane 2, Col G S3aS3b. Lane 3, ColGS3aS3b(S997C). Lane 4,
ColGS3aS3b(S997C) + biotin before avidin beads without UV light. Lane
5, supernatant of all protein not attached to biotin. Lane 6, ColGS3aS3b(S997C) with biotin after elution
from streptavidin beads. Lane 7, molecular weight marker (175, 80, 58, 46, 30, 25,17 kDa). The apparent
molecular weight of wildtype ColGS3aS3b is 32kDa (lane 2). The apparent molecular weight of
ColGS3aS3b(S997C) is 32 and 64 kDa, because it forms intermolecular disulfide bridge (lane 3). Still
apparent in the unpurified sample are unexplained lower molecular weight bands (lane 4). After addition to
streptavidin beads it becomes clear that the lower molecular weight bands were not attached to biotin (lane
5). Elution of biotin from the streptavidin beads, shows that the crosslinking was not successful because of
the lack of any bands (lane 6).
Figure 67. Mass Spectroscopy Analysis of
Biotin from 11/6/13 (11/27/13)
The lack of a peak at 32kDa shows that
somehow upon binding of the biotincrosslinker, the collagen binding domains
fragmented to pieces. This cleavage explains
the unexpected lower molecular weight bands.
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Figure 68. ColGS3aS3b(S997C) +Fluorescein (12/3/13)
The distribution of ColGS3aS3b(S997C) is clearly seen by using fluorescein
crosslinker. Lane 1, Col GS3aS3b(S997C) with fluorescein under UV light. Lane
2, molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa). The apparent
molecular weight of ColGS3aS3b(S997C) with fluorescein is 32kDa. The presence
of the lower molecular weight bands shows that this protein had undergone
cleavage by a protease, and therefore new protein was ordered and prepared by Dr.
Osamu Matsushita. While protein was being produced, experimentation with old
protein was done in order to gain experience with procedures.
Figure 69. Col GS3aS3b(S997C) +APDP + Rattus Type
I Collagen (Old protein, 1/21/14)
Photocrosslinked ColGS3aS3b(S997C) with APDP plus
rattus type I collagen analyzed by 7.5% gel. Lane 1,
molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa).
Lane 2, ColGS3aS3b(S997C) +APDP + rattus type I
collagen with no UV exposure. Lane 3, Col G S3aS3b
(S997C) +APDP + rattus type I collagen after UV
exposure. Lane 4, molecular weight marker (175, 80, 58,
46, 30, 25, 17 kDa). Lane 5, Col G S3aS3b (S997C)
+APDP + rattus type I collagen with DTT and no UV exposure. Lane 6, Col G S3aS3b (S997C) +APDP +
rattus type I collagen with DTT and UV exposure. The β chain of rattus type I collagen is represented by
the thicker double bands above the 175kDa marker band. The α chain of rattus type I collagen is
represented by the thicker double bands with the lower band having an approximate weight of 80kDa. The
band marked by the top arrow represents the crosslinking of tandem with the β chain, and the band marked
by the bottom arrow represents the crosslinking of tandem with the α chains (lane 3). The tandem dimer is
represented by the dark bands at the 42kDa (lane 2 and 3). Confirmation that the α and β crosslinking did
occur is shown after introducing DTT, which causes the breakdown of the disulfide bridge between the
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crosslinker and tandem. The crosslinked product at both the α and β chains and the dimer product
disappeared after reduction by DTT (lane 5 and 6).
Figure 70. ColGS3aS3b(S997C) +APDP + Rattus
Type I Collagen (Old protein, 1/24/14)
2-D diagonal electrophoresis of photocrosslinked
ColGS3aS3b(S997C) with APDP plus rattus type I
collagen. The arrows indicate where potential
crosslinking occurred on the α chains, but
crosslinking could not be seen on the β chains.

Figure 71. ColGS3aS3b(S997C) +APDP (New Protein,
1/30/14)
Confirmation of attachment of APDP to ColGS3aS3b(S997C).
Lane 1, molecular weight marker (175, 80, 58, 46, 30, 25, 17
kDa). Lane 2, ColGS3aS3b. Lane 3, ColGS3aS3b(S997C). Lane
4, reduced ColGS3aS3b(S997C). Lane 5, ColGS3aS3b(S997C)
with APDP after no UV radiation. Lane 6, ColGS3aS3b(S997C)
with APDP after UV radiation. Lane 7, molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa). The
apparent molecular weight of wildtype ColGS3aS3b is 32KDa (lane 2). The apparent molecular weight of
ColGS3aS3b(S997C) is 32kDa and 64kDa, because it forms intermolecular disulfide bridge (lane
3). Introducing DTT to ColGS3aS3b prevented the intermolecular disulfide bridge formation (lane 4).
After crosslinker attachment the disulfide bridge cannot be formed until exposed to UV (lane 5). UV
exposure using light source for 30 min triggered intermolecular cross-linking occurred and is shown by the
64kDa band (lane 6)
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Figure 72. ColGS3aS3b(S997C) +APDP + Rattus
Type I Collagen (New protein, 2/12/14)
Photocrosslinked ColGS3aS3b(S997C) with APDP
plus rattus type I collagen analyzed by 12% gel. Lane
1, molecular weight marker (175, 80, 58, 46, 30, 25,
17 KDa). Lane 2, ColGS3aS3b(S997C) +APDP +
rattus type I collagen with no UV exposure. Lane 3,
ColGS3aS3b(S997C) +APDP + rattus type I collagen
with UV exposure. Lane 4, molecular weight marker
(175, 80, 58, 46, 30, 25, 17 KDa). Lane 5,
ColGS3aS3b(S997C) +APDP + rattus type I collagen with DTT and no UV exposure. Lane 6,
ColGS3aS3b(S997C) +APDP + rattus type I collagen with DTT and UV exposure. The β chain of rattus
type I collagen is represented by the thicker double bands above the 175KDa marker band. The α chain of
rattus type I collagen is represented by the thicker double bands with the lower band having an approximate
weight of 80KDa. The band marked by the top arrow represents the crosslinking of tandem with the β
chain, and the band marked by the bottom arrow represents the crosslinking of tandem with the α chains
(lane 3). The tandem dimer is represented by the dark bands at the 42kDa (lane 2 and 3). Confirmation that
α and β crosslinking did occur is shown after introducing DTT, which causes the breakdown of the
disulfide bridge between the crosslinker and tandem. The crosslinked product at both the α and β chains
and the dimer product disappeared after reduction by DTT (lane 5 and 6).
Figure 73. ColGS3aS3b(S997C) +APDP + Rattus Type I
Collagen (New protein, 2/12/14)
Photocrosslinked ColGS3aS3b(S997C) with APDP plus rat
type I collagen analyzed by 7.5% gel. Lane 1, molecular
weight marker (175, 80, 58, 46, 30, 25, 17 kDa). Lane 2,
ColGS3aS3b(S997C) +APDP + rattus type I Collagen with no
UV exposure. Lane 3, ColGS3aS3b(S997C) + APDP + rattus
type I collagen with UV exposure. Lane 4, molecular weight
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marker (175, 80, 58, 46, 30, 25, 17 kDa). Lane 5, Col G S3aS3b (S997C) +APDP + rattus type I collagen
with DTT and no UV exposure. Lane 6, Col G S3aS3b (S997C) +APDP + rattus type I collagen with DTT
and UV exposure. The β chain of rattus type I collagen is represented by the thicker double bands above the
175 kDa marker band. The α chain of rattus type I collagen is represented by the thicker double bands with
the lower band having an approximate weight of 80kDa. Crosslinking did not occur because no additional
bands were created after UV exposure for 30 minutes (lane 3).
Figure 74. ColGS3aS3b(S997C) +APDP +
Rattus Type I Collagen (New protein,
2/12/14)
2-D diagonal electrophoresis of
photocrosslinked ColGS3aS3b(S997C) with
APDP plus rat type I collagen. According to
this analysis no crosslinking occurred. Gel
concentration could have not been high
enough to allow for the crosslinker to spread
out from the protein in order to observe the crosslinking.

Figure 75. Col GS3aS3b(S997C) + PEAS (New Protein,
1/30/14)
Confirmation of attachment of PEAS to
ColGS3aS3b(S997C). Lane 1, molecular weight marker
(175, 80, 58, 46, 30, 25, 17 kDa). Lane 2, ColGS3aS3b. Lane
3, ColGS3aS3b(S997C). Lane 4, reduced
ColGS3aS3b(S997C). Lane 5, ColGS3aS3b(S997C) with
PEAS after no UV radiation. Lane 6, ColGS3aS3b(S997C) with PEAS after UV radiation. Lane 7,
molecular weight marker (175, 80, 58, 46, 30, 25,17 kDa). The apparent molecular weight of wildtype
ColGS3aS3b is 32kDa (lane 2). The apparent molecular weight of ColGS3aS3b(S997C) is 32 and 64 kDa,
because it forms intermolecular disulfide bridge (lane 3). Introducing DTT to ColGS3aS3b prevented the
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intermolecular disulfide bridge formation (lane 4). After crosslinker attachment the disulfide bridge cannot
be formed until exposed to UV (lane 5). UV exposure using light source for 30 min triggered
intermolecular cross-linking occurred and is shown by the 64 kDa band (lane 6).
Figure 76. ColGS3aS3b(S997C) +PEAS + Bovine Type III
Collagen (New protein, 4/8/14)
Photocrosslinked ColGS3aS3b(S997C) with PEAS and bovine
type III collagen analyzed by 7.5% gel. Lane 1, ColGS3aS3b
(S997C) +PEAS + bovine type III collagen with no UV
exposure. Lane 2, ColGS3aS3b(S997C) + PEAS + bovine type
III collagen with UV exposure. Lane 3, molecular weight marker
(175, 80, 58, 46, 30, 25, 17 kDa). Lane 4, ColGS3aS3b(S997C)
+ PEAS + bovine type III collagen with DTT and no UV exposure. Lane 5, ColGS3aS3b(S997C) + PEAS
+ bovine type III collagen with DTT and UV exposure. Lane 6, molecular weight marker (175, 80, 58, 46,
30, 25, 17 kDa). Crosslinking did not occur because no additional bands were created after UV exposure
for 30 minutes (lane 2).
Figure 77. ColGS3aS3b(S997C) +PEAS + Rattus Type I
Collagen (New protein, 4/8/14)
Photocrosslinked ColGS3aS3b(S997C) with PEAS and rattus
type I collagen analyzed by 7.5% gel. Lane 1, ColGS3aS3b
(S997C) +PEAS + rattus type I collagen with no UV exposure.
Lane 2, ColGS3aS3b(S997C) +PEAS + rattus type I collagen
with UV exposure. Lane 3, molecular weight marker (175, 80,
58, 46, 30, 25, 17 kDa). Lane 4, ColGS3aS3b(S997C) +PEAS +
rattus type I collagen with DTT and no UV exposure. Lane 5, ColGS3aS3b(S997C) +PEAS + rattus type I
collagen with DTT and UV exposure. Lane 6, molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa).
The β chain of rattus type I collagen is represented by the thicker double bands above the 175kDa marker
band. The α chain of rattus type I collagen is represented by the thicker double bands with the lower band
having an approximate weight of 80kDa. The arrow indicates crosslinking to α chain (lane 2). The tandem
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dimer is represented by the dark bands at the 42kDa (lane 1 and 2). Confirmation that the α crosslinking did
occur is shown after introducing DTT, which causes the breakdown of the disulfide bridge between the
crosslinker and tandem. The cross-linked product on the α chain and the dimer product disappeared after
reduction by DTT (lane 4 and 5).
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Figure 78. Col GS3aS3b(S997C) +APDP + rattus type I collagen (New Protein, 5/1/14)
Fibril formation assay performed in order to determine if incubation time is long enough for collagen fibril
formation. According to the data it can be seen that 30 minutes is sufficiently long enough for the collagen
fibril to form in the presence of ColGS3aS3b(S997C) +APDP. Interfering with fibril formation
Figure 79. ColGS3aS3b (S997C) +Fluorescein (9/12/14)
The distribution of ColGS3aS3b(S997C) is clearly seen using the fluorescein crosslinker.
Lane 1, ColGS3aS3b(S997C) with fluorescein under UV light. Lane 2, molecular weight
marker (175, 80, 58, 46, 30, 25, 17 kDa). The apparent molecular weight of
ColGS3aS3b(S997C) with fluorescein is 32kDa. This photo does not clearly show the band
that was present at 32kDa. However, it can be seen that all the lower molecular weight
bands are missing from the protein so this new protein has not been cleaved by a protease.
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Figure 80. ColGS3aS3b(S997C) + Fluorescein
+Pancreatic Cancer Cells (9/13/14)
After addition of fluorescein attached
ColGS3aS3b(S997C) it is becomes clear that
ColGS3aS3b(S997C) binds to the extracellular
matrix of the cancer cells.

Figure 81. ColGS3aS3b(S997C) +APDP (New Protein, 9/18/14)
Confirmation of attachment of APDP to ColGS3aS3b(S997C).
Lane 1, molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa).
Lane 2, ColGS3aS3b. Lane 3, ColGS3aS3b(S997C). Lane 4,
reduced ColGS3aS3b(S997C). Lane 5, ColGS3aS3b(S997C) with
APDP after no UV radiation. Lane 6, ColGS3aS3b(S997C) with
APDP after UV radiation. Lane 7, molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa). The apparent
molecular weight of wild type ColGS3aS3b is 32KDa (lane 2). The apparent molecular weight of
ColGS3aS3b(S997C) is 32 and 64 kDa, because it forms intermolecular disulfide bridge (lane
3). Introducing DTT to ColGS3aS3b prevented the intermolecular disulfide bridge formation (lane 4).
After crosslinker attachment the disulfide bridge cannot be formed until exposed to UV (lane 5). UV
exposure using light source for 30 min triggered intermolecular cross-linking occurred and is shown by the
64kDa band (lane 6).
Figure 82. Col G S3aS3b (S997C) +APDP + Rattus Type I
Collagen (New protein, 9/18/14)
Photocrosslinked ColGS3aS3b(S997C) with APDP plus rattus
type I collagen analyzed by 12% gel. Lane 1, molecular
weight marker (175, 80, 58, 46, 30, 25,17 kDa). Lane 2,
ColGS3aS3b(S997C) +APDP + rattus type I collagen with no
UV exposure. Lane 3, ColGS3aS3b(S997C) +APDP + rattus
type I collagen with UV exposure. Lane 4, molecular weight
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marker (175, 80, 58, 46, 30, 25, 17 kDa). Lane 5, ColGS3aS3b(S997C) +APDP + rattus type I collagen
with DTT and no UV exposure. Lane 6, ColGS3aS3b(S997C) +APDP + rattus type I collagen with DTT
and UV exposure. The β chain of rattus type I collagen is represented by the thicker double bands above the
175 kDa marker band. The α chain of rattus type I collagen is represented by the thicker double bands with
the lower band having an approximate weight of 80kDa. The band marked by the top arrow represents the
crosslinking of tandem with the β chain, and the band marked by the bottom arrow represents the
crosslinking of tandem with the α chains (lane 3). Confirmation that α and β crosslinking did occur is
shown after introducing DTT, which causes the breakdown of the disulfide bridge between the crosslinker
and tandem. The crosslinked product at both the α and β chains disappeared after reduction by DTT (lane 5
and 6).
Figure 83. ColGS3aS3b(Y996A,S997C) + APDP
(New Protein, 9/18/14)
Confirmation of attachment of APDP to
ColGS3aS3b(Y996A,S997C). Lane 1, molecular
weight marker (175, 80, 58, 46, 30, 25, 17 kDa). Lane
2, Col G S3aS3b. Lane 3,
ColGS3aS3b(Y996A,S997C). Lane 4, reduced
ColGS3aS3b(Y996A,S997C). Lane 5,
ColGS3aS3b(Y996A, S997C) with APDP after no UV radiation. Lane 6, ColGS3aS3b(Y996A,S997C)
with APDP after UV radiation. Lane 7, molecular weight marker (175, 80, 58, 46, 30, 25, 17 kDa). The
apparent molecular weight of wildtype ColGS3aS3b is 32kDa (lane 2). The apparent molecular weight of
ColGS3aS3b(Y996A,S997C) is 32 and 64 kDa, because it forms intermolecular disulfide bridge (lane
3). Introducing DTT to ColGS3aS3b prevented the intermolecular disulfide bridge formation (lane 4).
After crosslinker attachment the disulfide bridge cannot be formed until exposed to UV (lane 5). UV
exposure using light source for 30 min triggered intermolecular cross-linking occurred and is shown by the
64kDa band (lane 6).
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Figure 84. ColGS3aS3b(S997C) +Fluorescien (9/18/14)
Studying the distribution of ColGS3aS3b(S997C) using fluorescein crosslinker. Lane 1,
ColGS3aS3b(S997C) with fluorescein under UV light. Lane 2, molecular weight marker
(175, 80, 58, 46, 30, 25, 17 kDa). The apparent molecular weight of ColGS3aS3b(S997C)
with fluorescein is 32kDa. This photo clearly shows the molecular weight of
ColGS3aS3b(S997C) at 32kDa.

Figure 85. ColGS3aS3b(Y996A,S997C) +Fluorescien (9/18/14)
Studying the distribution of Col G S3aS3b (Y996A/S997C) using fluorescein crosslinker.
Lane 1, ColGS3aS3b(Y996A/S997C) with fluorescein under UV light. Lane 2, molecular
weight marker (175, 80, 58, 46, 30, 25, 17 kDa). The apparent molecular weight of
ColGS3aS3b(Y996A,S997C) with fluorescein is 32kDa.

Figure 86. ColGS3aS3b(S997C) +APDP + Rattus Type
I Collagen (New protein, 11/7/14)
Mass production of 8 gels with 10 wells each, all
containing APDP attached ColGS3aS3b(S997C) with
rattus type I collagen after UV radiation. The α1, α2, and
complex bands were cut out of the gel and sent to mass
spectrometry facilities for analysis.
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Figure 87. Sequence of rattus type I collagen labeled with possible binding sites from mass
spectrometry analysis.
Rattus type I collagen sequence aligned to show collagen fibril formation. Red box indicates the most
probable binding site, because crosslinked amino acid for α1 and α2 are within three amino acids of
eachother. Also, the peptide fragments were confirmed by both Mascot and Skyline software. The orange
regions indicate predicted undertwisted regions. As can be seen the red box is located in one of predicted
undertwisted regions, which adds support to the hypothesis that collagenases bind to undertwisted regions
in collagen. After plotting the possible binding sites on a map of ligand binding sites, it was determined that
tandem CBD binds in close proximity to interleukin-2 and integrin binding sites [4].

VI. Discussion
Tandem CBD from ColG binds collagen tighter than all the other clostridial
collagen binders. Uchida et al. has recently shown that a tighter binding CBD construct
fused with basic fibroblast growth factor enhances periosteal bone formation [13]. The
tandem CBD from Col G binds tighter to collagen than the construct used by Uchida’s
study suggesting that when used it could be more potent in osteogenesis. My research is
part of a scheme to understand and to develop novel wound healing in collaboration with
various labs and Nippi Inc.
Philominathan et al. observed that CBD binds to undertwisted regions of

collagen using NMR and SAXS [17]. It was first shown that CBD only binds at the Cterminus of mini-collagen. However, in earlier experiments using gold-labeled CBD,
Toyoshima et al. showed that CBD could bind to more sites than just the C-terminus of
tropocollagen [18]. This promoted further experimentation by Philominathan et al. These
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experiments showed that CBD binds to collagen at undertwisted regions in the middle as
well as at the C-terminus [8]. It was also seen that CBD binds without causing any
structural changes and, therefore, does not facilitate the unwinding of collagen fibers.
Yasui and Koide developed a method using photoreactive crosslinkers to determine
protein binding sites on collagen [16]. It has been speculated that tropocollagne consists
of five to six undertwisted regions. It was expected that the same procedure could be used
to determine which undertwisted regions the CBD preferred to bind.
In order attach a crosslinker specifically at the lip of the collagen binding pocket
of CBD, overlap extension PCR was used to introduce a cysteine mutation in order to
allow crosslinker attachment. Using the following method it was confirmed that
polymerase chain reactions successfully introduced the desired mutations into each
plasmid DNA for all mutagenesis projects, which included ColGS3aS3b (S997C),
ColGS3aS3b (Y996A,S997C), and ColGS3aS3b (Y994A,S997C) The Big Dye
Terminator v1.1 Cycle Sequencing Kit was used to prepare DNA for a sequencing
machine. After determining the sequences from the chromatograms obtained from the
sequencing machine, the experimental DNA strand sequences and expected DNA
sequences were compared and all mutants were confirmed to have the proper nucleotide
orientation.
Afterwards, the above mutants along with Col GS3aS3b, ColGS3a (S879C),
ColGS3aS3b (S879C), ColGS3b (Y996A,S997C) were successfully overexpressed and
purified, following similar protocol used by Osamu Matsushita, M.D./Ph.D. [10].
Successful production of the proteins was also observed after analysis by SDS-PAGE. A
band was present on the gels that showed that the proteins contained the proper molecular
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weight. Also bands appeared to on the gel to show that the cysteine mutation was
introduced.
Following the procedure developed by Yasui and Koide and modified by Keisuke
Tanaka, several different crosslinking experiments were performed [16] . The results
from SDS-PAGE showed that four different crosslinkers successfully attached to the
introduced cysteine mutations of ColGS3aS3b(S997C). Crosslinker attachment was
observed by comparing the masses of mutant CBD without crosslinker to mutant CBD
with crosslinker displayed on SDS-PAGE. SDS-PAGE also showed that
ColGS3aS3b(S997C) could no longer form dimers without UV exposure. After UV
exposure dimer formation became possible again. These two properties are indicative of
photocrosslinked cysteine mutations. Even though the crosslinkers were able to
successfully attach not all of them were suitable for further studies. A biotin crosslinker
was used in an attempt to purify the collagen-CBD complex. For unexplained reasons,
the biotin crosslinker caused fragmentation of the protein upon binding to
ColGS3aS3b(S997C). In order to rule out protease activity, another experiment was
performed with a buffer that prevents proteolytic activity and the same results occurred.
Therefore, this fragmentation could have been due to the size of the larger substituents,
such as benzophene and biotin. Also, the purification column was unsuccessful.
After repeating several different crosslinking assays with APDP and PEAS
attached CBD, it became clear that APDP produced the most consistent results. Even
though it appeared that PEAS had become bound to CBD it was unsuccessful in
crosslinking assays with rattus type I and bovine type III collagen. Looking at Figure 75,
it can be seen in lane 6 that the dimer product of the PEAS attached CBD is lower in
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concentration then all the other bands that appear on the gel. This could explain why the
crosslinking assays were unsuccessful. The correct PEAS attached CBD product was in
such low concentrations that it was unable to make the necessary contacts and bind to
collagen. Among all the crosslinkers, fluorescein consistently attached and showed the
distribution. It was also successfully used in remodeling collagen studies. Therefore,
APDP and fluorescein were used in crosslinking experiments with the control protein,
ColGS3aS3b(Y996A,S997C). The crosslinker attachment was confirmed using similar
methods to those done for ColGS3aS3b(S997C).
Rattus type I collagen and bovine type III collagen provided by Nippi Inc, were
used in different crosslinking assays. Type I collagen is heterotrimer with two α1 chains
and one α2 chain. The former offers some advantages because it is abundant and a
previous study showed that CBD binds to both skin and bone that are rich in type I
collagen [4]. In comparison type III collagen is rare but a homotrimer, and therefore
could make analysis simpler. The crosslinking assays were analyzed by SDS-PAGE
under both non-reduced and reduced conditions. Upon UV exposure, the APDP attached
ColGS3aS3b(S997C) crosslinked to the α1 region of rattus type I collagen, which would
appear as a band between the α1 and β2 bands of rattus type I collagen. Also, APDP
attached ColGS3aS3b(S997C) crosslinked to the β1 region of collagen, which is observed
as a higher molecular weight band above the β1 band. The reduced conditions showed the
disappearance of these bands, and, therefore, confirmed the crosslinking had been
successful. Reduction reduces the disulfide bridge between the crosslinker and collagen
and therefore the band disappears. The PEAS attached CBD did not successfully bind to
bovine type III or rattus type I collagen. Since the PEAS crosslinker was not successful
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for both types of collagen it cannot be determined which collagen produced the best
results. Further experimentation should be done with APDP attached CBD in order to
determine which collagen provides the best results.
After performing the crosslinking assay, the Yasui and Koide method used 2-D
electrophoresis to analyze where the proteins became bound to collagen. However, in
order to perform a more specific and detailed analysis of where CBD binds to collagen it
was expected that mass spectrometry could be used for analysis. In order to do this the
the cross-linked CBD-collagen complex was subjected to digestion by trypsin. After
analysis of mass spectrometry results, it was determined that this procedure was
successful and, therefore, Yasui and Koide’s method was improved upon. This new
procedure can be used to study other molecular pathways in order to help in the fight for
disease prevention.
The results from mass spectrometry show that tandem CBD binds to both the α1
and α2 bands of collagen, possibly through the formation of a complex. The data results
from comparison of multiple samples. If multiple samples contained the same tryptic
fragment identification, it was considered less likely to be a false positive. Multiple
samples show that binding occurs in the α1 chain for the peptide sequence
K.GEPGPAGVQGPPGPAGEEGK.R [270, 289]. This peptide sequence is confirmed by
both the Mascot and Skyline software. For the α2 chain, the peptide sequence
R.GSPGEPGSAGPAGPPGLR.G [292,309] is also confirmed by many samples. After
plotting the collagen sequence, it is seen that the binding amino acids from the α1 and α2
chains are within three amino acids from each other. This observation strengthens our
assumption that this is the most probable binding site.

78

After further examination, this peptide fragment is located in a region of collagen
that was predicted to contain undertwisted collagen fibrils. This observation indicates that
CBD might actually be binding to undertwisted regions, not only in synthesized mini
collagen, but also in the full collagen protein. Also, it appears that CBD binds in regions
near interleukin 2 and integrin binding sites, which are located on the α1 and α2 chain
respectively. This observation indicates that using tandem CBD as a drug delivery
system could result in negative side effects, however only further experimentation will
confirm this assumption.
Upon comparison to work done by Keisuke Tanaka with ColGS3b domain, it is
shown that he had located the same binding site while experimenting with bovine
collagen and the PEAS crosslinker. This comparison is significant because the cysteine
mutation introduce into the tandem CBD is located in the S3b domain. Therefore, it is
expected that they should bind to similar locations on collagen. This assumption was
proven to be correct because both experiments showed binding to the same peptide
fragment. Also, since the results were similar specificity caused by crosslinker and
collagen type can be ruled because different crosslinkers and type of collagens were used.
Remodeling collagen is necessary for tissue development, regeneration and
maintenance. However, in excess this remodeling can lead to several pathological
conditions including cancer [7] . Remodeling collagen consists of undertwisted regions. It
was expected that CBD could bind to the undertwisted region and be used for in vivo and
in vitro analysis of cancer cells.
In order to confirm that CBD can bind to remodeling collagen in cancer cells,
fluorescein attached ColGS3aS3b(S997C) was used to target remodeling collagen in
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vitro. After introducing fluorescein attached ColGS3aS3b(S997C) it became clear that
tandem CBD recognized collagen secreted by pancreatic cells and became bound to the
extracellular matrix of the cells. A control, fluorescein attached
ColGS3aS3b(Y996A,S997C) was used and showed that it was in fact the fluorescein
attached ColGS3aS3b(S997C) that became bound to the outer part of the cell.
In summary, I was able to generate five mutants to lay foundation for studying the
tandem CBD. The tandem CBD binds to collagen the tightest among bacterial
collagenase derived collagen binders. X-ray structure of the tandem CBD suggests that it
achieves its binding by possibly wedging itself between collagen fibril. Mass
spectrometry results confirmed this assumption because the identified binding site is
located within the collagen fibril. Also, mass spectrometry showed that it binds to both α1
and α2 bands of collagen. In addition, the analysis of the CBD as a diagnostic and
therapeutic protein for cancer involving fluorescein attached ColGS3aS3b(S997C) looks
promising.
Future experiments will include observing fluorescein attached
ColGS3aS3b(S997C) in human pancreatic tissue, which is expected to show binding of
CBD to human tissue. These experiments will provide more insight into using the tandem
CBD as an imaging technique or for repairing tissues after cancer cell death. Also this
could lead to using CBD as a delivery system with a toxin to kill cancer cells.
Along with those experiments, one more crosslinking experiment with APDP and
rattus type I collagen should be done in order to solidify the findings of our previous
experiments. Also, crosslinking to the β chain should be determined using rattus type I
collagen. Additionally, more crosslinking experiments using APDP attached
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ColGS3aS3b(S997C) should be performed with bovine and porcine derived type I
collagen molecules. These type I collagen share 95% sequence identity and are predicted
to possess six underwound regions, thus should result in similar outcome. Experiments
should be done to identify the binding preference for tandem CBD to MMP fragment.
Furthermore, crosslinking experiments need to be done using the other mutants produced
so that it can be determined where S3a binds.
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